Introduction {#s1}
============

After birth, the skeleton sustains a period of exuberant longitudinal and periosteal growth, the respective processes by which bones grow in length and width ([@bib46]). Since increased length and increased width have opposite effects on susceptibility to fracture, longitudinal and periosteal growth must be tightly coupled to build a skeleton that supports body weight and motion during postnatal life ([@bib40]; [@bib9]). Longitudinal growth is mediated by growth plate cartilage. Defects in longitudinal growth are well documented in the dwarfism resulting from genetic mutations of FGFR3 (MIM100800) ([@bib39]), PTHR1 (MIM156400) ([@bib48]), or GDF5 (MIM200700) ([@bib46]). Periosteal growth is mediated by the periosteum. Although excessive periosteal bone formation is linked to activating mutations of the canonical WNT pathway ([@bib1]), accounts of defective periosteal growth in humans are extremely rare ([@bib2]). The identity of the essential signal governing periosteal activity during early postnatal life therefore remains unknown. It also remains unclear whether functions of the adult periosteum, including fracture repair and cortical expansion in response to therapeutic agents, rely on reactivation of this putative developmental signal.

The periosteum is a stratified fibro-cellular structure that adds tissue to the exterior surfaces of bone, much like rings on the trunk of an actively growing tree ([@bib14]). The outer periosteum provides a collagen-rich barrier between muscle and the underlying bone and is the site of insertion for tendons and ligaments. It is highly vascularized, innervated, and sparsely populated by fibroblasts. The cambium, or inner periosteal layer adjacent to bone, is a repository for self-renewing skeletal progenitors that differentiate into bone-forming osteoblasts ([@bib14]). The periosteum is thick and highly active during pre-pubertal growth but becomes thin and largely quiescent in adult life. The molecular mechanism controlling the conversion between active and quiescent periosteal states is not well understood.

Since *Bmp2* is essential for initiation of fracture repair ([@bib52]), we hypothesized that *Bmp2* governs all major developmental and inducible functions of the periosteal niche. To test this, we performed skeletal phenotype analysis of mice where *Bmp2* was selectively ablated in progenitor, committed, or mature osteoblast populations. We mapped the endogenous *Bmp2* expression domain and compared this to the BMP signaling domain during skeletal development and homeostasis. Periosteal growth and fracture phenotypes of *Bmp2* mutant mice were monitored following genetic or pharmacologic activation of the LRP5/6 signaling pathway. We investigated recruitment of pathway-specific transcription factors to genome-wide cis-regulatory elements, establishing at the molecular level the epistatic relationship between canonical WNT and BMP2 signaling during osteoblast differentiation. And finally, we performed phenome wide analysis to test links between our preclinical data and fracture risk in clinical settings.

Results {#s2}
=======

Osteoprogenitor-derived BMP2 couples longitudinal to periosteal bone growth {#s2-1}
---------------------------------------------------------------------------

Removal of *Bmp2* from the developing mouse limb (*Bmp2^Flox/Flox^; Prx1-Cre*) causes spontaneous fractures that do not heal ([@bib52]). Fracture repair and bone graft healing were rescued in *Bmp2*-deficient bones by provision of recombinant BMP2 ([@bib6]), however the underlying cause of the spontaneous fractures remained unknown. During skeletal phenotyping, microcomputed tomography (microCT) revealed that *Bmp2^Flox/Flox^* (WT) femurs ([Figure 1a](#fig1){ref-type="fig"}) and *Bmp2^Flox/Flox^; Prx1-Cre* (*Bmp2* Prx1-cKO) femurs ([Figure 1b](#fig1){ref-type="fig"}) were indistinguishable at birth. *Bmp2* Prx1-cKO femurs developed a striking geometry after birth, characterized by near normal length ([Figure 1c](#fig1){ref-type="fig"}) but narrow width ([Figure 1d](#fig1){ref-type="fig"}). In the radius/ulna, defective periosteal bone growth was not evident at birth ([Figure 1e--f](#fig1){ref-type="fig"}), but appeared by 2 weeks of age ([Figure 1g--h](#fig1){ref-type="fig"}) and remained unresolved during adult life. The radius/ulna of WT and *Bmp2* Prx1-cKO mice contained similar proportions of cortical bone and medullary space at birth ([Figure 1i](#fig1){ref-type="fig"}). By 2 weeks, forelimb structures of *Bmp2* Prx1-cKO mice were composed primarily of cortical bone ([Figure 1j](#fig1){ref-type="fig"}) despite the total cross-sectional area being dramatically reduced compared to controls. This slender bone phenotype was not restricted to the radius/ulna ([Figure 1g](#fig1){ref-type="fig"}) and femur ([Figure 1k](#fig1){ref-type="fig"}) but appeared at all appendicular skeletal sites including the tibia ([Figure 1l](#fig1){ref-type="fig"}) and metatarsals ([Figure 1m](#fig1){ref-type="fig"}). Osteopenia was not evident in the axial skeleton where *Prx1-Cre* is not active ([@bib13]; [@bib27]).

![Osteoprogenitor-derived *Bmp2* couples length to width in the appendicular skeleton.\
(**a,b**) Representative 3D reconstructions of the murine femur using microcomputed tomography (microCT). (**c**) Femoral length or (**d**) femoral width at mid-diaphysis, presented as mean ± s.d. with *n* = 8--20 bones per age per genotype. \*p\<0.05, \*\*p\<0.005, or \*\*\*p\<0.0005 vs. age-matched *Bmp2* Prx1-cKO cohort. (**e,g**) Representative toluidine blue histology at the mid-diaphysis of the forelimb. (**f,h**) MicroCT analysis of total cross-sectional bone tissue area presented as mean ±s.d. with *n* = 4. \*p\>0.05. (**i,j**) Cross-sectional composition of cortical bone in the radius of newborn (*n* = 6--9 per genotype) or 2 week-old mice (*n* = 3--9 per genotype) (see Materials and methods). Abbreviations: PC, perichondrium; PO, periosteum. (**k,l,m**) Representative toluidine blue histology at the mid-diaphysis of indicated skeletal elements. (**n**) Length or (**o**) width of embryonic day 15 metatarsals, measured following 1 or 5 days of ex vivo culture. Mean ±s.d. with *n* = 6--12 where \*\*p\<0.005, \*\*\*p\<0.005, or \*\*\*\*p\<0.00005. (**p,q,r**) Femur width mean ±s.d. with *n* = 6--12 where \*p\<0.05. (**s**) Minimum moment of inertia in P14 femur, calculated by microCT (*n* = 4) shown as mean ±s.d. where \*\*\*p\<0.0005. (**t**) Toludine blue histology revealing cortical microcracks in the humerus of *Bmp2* Prx1-cKO mice at 4 weeks of age. (**u**) X-ray images showing representative bowing of the radius and ulna of *Bmp2* Prx1-cKO mice in the absence of frank fractures. Statistical analyses were performed using two-tailed Student's *t*-test.](elife-42386-fig1){#fig1}

Defective periosteal bone growth occurred in males and females and was therefore unlikely to be caused by sex hormones. IGF-1 signaling can affect bone width ([@bib26]), but *Bmp2* Prx1-cKO mice expressed IGF-1 in bone ([Figure 1---figure supplement 1a](#fig1s1){ref-type="fig"}) and circulating IGF-1 was statistically unchanged in *Bmp2* Prx1-cKO mice ([Figure 1---figure supplement 1b](#fig1s1){ref-type="fig"}). During ex vivo organ culture, WT and *Bmp2* Prx1-cKO metatarsals were equal in length on day one and both grew in culture ([Figure 1n](#fig1){ref-type="fig"}). WT and *Bmp2* Prx1-cKO metatarsals were equal in width on day 1, but only WT metatarsals grew in width during culture ([Figure 1o](#fig1){ref-type="fig"}).

*Bmp2* is essential for conversion of *Runx2+* osteoprogenitors to the *Sp7+* osteoblast cell fate in primary cell models ([@bib47]). Consistent with these in vitro observations, mice with conditional ablation of *Bmp2* in skeletal progenitors (*Bmp2* Prx1-cKO) ([Figure 1p](#fig1){ref-type="fig"}), but not committed osteoblasts (*Bmp2^Flox/Flox^; Sp7-GFP::Cre* or *Bmp2* Sp7-cKO) ([Figure 1q](#fig1){ref-type="fig"}) or mature osteoblasts (*Bmp2^Flox/Flox^; 2.3kbCol1a1-*Cre or *Bmp2* Col1a1-cKO) ([Figure 1r](#fig1){ref-type="fig"}) showed periosteal growth defects at 2 weeks of age. *Bmp2* Col1a1-cKO mice exhibited no differences in skeletal phenotype when qualitatively examined by whole mount skeletal staining at birth ([Figure 1---figure supplement 2a--b](#fig1s2){ref-type="fig"}), histology of forelimb ([Figure 1---figure supplement 2c](#fig1s2){ref-type="fig"}) or hindlimb ([Figure 1---figure supplement 2d](#fig1s2){ref-type="fig"}) at 2 weeks of age, or X-ray imaging at 3 months of age ([Figure 1---figure supplement 2e](#fig1s2){ref-type="fig"}). Quantitative analysis of the femur at 2 weeks of age showed no changes in length, width ([Figure 1---figure supplement 2f](#fig1s2){ref-type="fig"}) or other standard parameters of trabecular bone volume fraction of the distal metaphysis and cortical cross-sectional area of the mid-shaft ([Table 1](#table1){ref-type="table"}).

10.7554/eLife.42386.006

###### Skeletal phenotype analysis of *Bmp2^Flox/Flox^; Col1a1-Cre* mice shows that loss of *Bmp2* in mature osteoblasts does not cause a periosteal growth defect.

Bone mass analyzed in the femur of juvenile 2 week-old mice by microCT. Data presented as mean ±s.d. with no statistical differences detected between WT and conditional knockout mice using 1-way ANOVA. Abbreviations: BV/TV, trabecular bone volume to total tissue volume; Tb.Th, trabecular thickness; Tb.Sp. trabecular spacing; Tb.N. trabecular number; Tt.Ar, total cross-sectional tissue area at the mid-diaphysis; Ct.Ar, cortical bone area; Ct.Ar/Tt.Ar, cortical bone area as a fraction of total tissue area; C.Th cortical thickness; *I*~MIN~, minimum moment of inertia.

  MicroCT femur, P14   *Bmp2^Flox/Flox^*   *Bmp2^Flox/Flox^; Col1a1-Cre*
  -------------------- ------------------- -------------------------------
  N                    4                   4
  BV/TV (%)            7.9 ± 1.0           7.5 ± 0.6
  Tb.Th (mm)           0.026 ± 0.002       0.026 ± 0.006
  Tb.Sp. (mm)          0.361 ± 0.037       0.399 ± 0.058
  Tb.N (1/mm)          2.89 ± 0.307        2.63 ± 0.35
  Tt.Ar (mm^2^)        1.17 ± 0.08         1.15 ± 0.078
  Ct.Ar (mm^2^)        0.322 ± 0.052       0.301 ± 0.018
  Ct.Ar/Tt.Ar (%)      27 ± 0.08           25 ± 0.08
  C.Th (mm)            0.081 ± 0.006       0.078 ± 0.007
  *I*min (mm^4^)       0.040 ± 0.007       0.038 ± 0.002

Geometric abnormalities plus material defects underlie spontaneous fractures in *Bmp2^Flox/Flox^; Prx1-Cre* mice {#s2-2}
----------------------------------------------------------------------------------------------------------------

Beyond the slender bone phenotype, *Bmp2* Prx1-cKO mice exhibited no differences in skeletal patterning when imaged by X-ray at 3 months of age ([Figure 1---figure supplement 3a](#fig1s3){ref-type="fig"}). Closer examination of *Bmp2* Prx1-cKO bones at 2 weeks of age by microCT revealed trabecular bone content and tissue mineral density were unaffected by the absence of *Bmp2* ([Figure 1---figure supplement 3b](#fig1s3){ref-type="fig"} and [Table 2](#table2){ref-type="table"}), despite significant reductions in bone width ([Figure 1---figure supplement 3c](#fig1s3){ref-type="fig"}), total cross-sectional area (Tt.Ar), marrow area (Ma.Ar), and minimum moment of inertia (*I*~MIN~) ([Table 2](#table2){ref-type="table"}). Static histomorphometry disclosed decreased numbers of osteoblasts but not osteoclasts per unit of bone surface ([Figure 1---figure supplement 3d](#fig1s3){ref-type="fig"}). Bone formation and mineral apposition rates were similar at endosteal sites but dramatically reduced at periosteal sites in *Bmp2* Prx1-cKO mice ([Figure 1---figure supplement 3e--h](#fig1s3){ref-type="fig"}). We found abundant cortical porosity ([Figure 1---figure supplement 3i](#fig1s3){ref-type="fig"}) with residual islands of cartilage and excessive numbers of osteocytes in *Bmp2* Prx1-cKO bones ([Figure 1---figure supplement 3j](#fig1s3){ref-type="fig"}). Under polarizing light microcopy, collagen in *Bmp2* Prx1-cKO cortical bone had a woven appearance compared to lamellar organization in WT bone ([Figure 1---figure supplement 3k,l](#fig1s3){ref-type="fig"}). *Bmp2* Prx1-cKO bones had increased osteoid thickness and a prolonged mineralization lag time on periosteal but not endosteal surfaces ([Figure 1---figure supplement 3m--p](#fig1s3){ref-type="fig"}).

10.7554/eLife.42386.007

###### Skeletal phenotype of 2 week-old *Bmp2^Flox/Flox^; Prx1-Cre* mice.

Quantitative microCT data presented as mean ±s.d. where \*\*\*p\<0.0005 vs. age-matched *Bmp2^F/F^* littermates when compared by 1-way ANOVA. (**e**) Static histomorphometry (*n* = 4), presented as mean ±s.d. \*p\<0.05 vs. age-matched *Bmp2^F/F^* littermates. Abbreviations: BV/TV, trabecular bone volume to total tissue volume; Tb.Th, trabecular thickness; Tb.Sp. trabecular spacing; Tb.N. trabecular number; Tt.Ar, total cross-sectional tissue area at the mid-diaphysis; Ct.Ar, cortical bone area; Ct.Ar/Tt.Ar, cortical bone area as a fraction of total tissue area; C.Th cortical thickness; Ma.Ar, marrow area; *I*~MIN~, minimum moment of inertia; TMD, tissue mineral density.

  MicroCT femur, P14   *Bmp2^Flox/Flox^*   *Bmp2^Flox/Flox^; Prx1-Cre*
  -------------------- ------------------- -----------------------------
  N                    4                   4
  BV/TV (%)            4.3 ± 1.0           6.6 ± 0.9
  Tb.Th (mm)           0.02 ± 0.001        0.02 ± 0.001
  Tb.Sp. (mm)          0.35 ± 0.04         0.26 ± 0.06
  Tb.N (1/mm)          2.8 ± 0.3           3.9 ± 1.0
  Tt.Ar (mm^2^)        1.02 ± 0.08         0.6 ± 0.03\*\*\*
  Ct.Ar (mm^2^)        0.24 ± 0.03         0.21 ± 0.01
  Ct.Ar/Tt.Ar (%)      23 ± 0.2            36 ± 1.0\*\*\*
  C.Th (mm)            0.065 ± 0.07        0.06 ± 0.03
  Ma.Ar (mm^2^)        0.46 ± 0.04         0.23 ± 0.02\*\*\*
  *I*min (mm^4^)       0.02 ± 0.005        0.01 ± 0.001\*\*\*
  TMD (mgHA/cm^3^)     882.6 ± 20.6        858.7 ± 8.57

Overall, dramatically reduced polar moment of inertia ([Figure 1---figure supplement 1s](#fig1s1){ref-type="fig"}) and impaired material properties of *Bmp2* Prx1-cKO bones likely caused microcracks ([Figure 1t](#fig1){ref-type="fig"}) and bowing ([Figure 1u](#fig1){ref-type="fig"}), factors preceding onset of frank fractures ([@bib52]).

*Bmp2* is expressed at the right time and place to regulate periosteum formation and/or function {#s2-3}
------------------------------------------------------------------------------------------------

We used a bacterial *beta-galactosidase (lacz)* reporter expressed from the endogenous *Bmp2* locus (*Bmp2^lacz/+^)* to map the skeletal *Bmp2* expression domain ([Figure 2---figure supplement 1a--c](#fig2s1){ref-type="fig"}). At E13.5, LacZ was highly expressed in the ribs, scapula, clavicles, forelimbs, hindlimbs, and portions of the craniofacial vault ([Figure 2a](#fig2){ref-type="fig"}). At E14.5, LacZ+ cells surrounded the cartilage anlagen where the presumptive bone collar forms ([Figure 2b--c](#fig2){ref-type="fig"}, [Figure 2---figure supplement 2a](#fig2s2){ref-type="fig"}). At birth, LacZ+ cells populated the bone collar, perichondrium, hypertrophic cartilage and Groove of Ranvier ([Figure 2d--e](#fig2){ref-type="fig"}, [Figure 2---figure supplement 2b](#fig2s2){ref-type="fig"}). Although expecting to see strong LacZ activity in the periosteum during the first 2 weeks of life, we instead made the surprising observation that LacZ+ cells in the periosteum were rare and appeared only in the cambium, immediately adjacent to or just below the outer bone surface ([Figure 2f--g](#fig2){ref-type="fig"}, [Figure 2---figure supplement 2c](#fig2s2){ref-type="fig"}). Most cortical osteocytes were LacZ+ while cells on the cortical endosteum were LacZ- ([Figure 2f--i](#fig2){ref-type="fig"}). LacZ activity became progressively restricted to the cortical/periosteal interface as mice approached peak body size and entered skeletal homeostasis ([Figure 2h--i](#fig2){ref-type="fig"}) but was reactivated locally following fracture ([Figure 2j--l](#fig2){ref-type="fig"}).

![Robust versus quiescent states of *Bmp2* expression reflect active versus homeostatic states of periosteal bone growth.\
LacZ staining on tissues from mice expressing *beta-galactosidase* from one allele of the endogenous *Bmp2* locus (*Bmp2^lacz/+^*). (**a**) Lateral view of a whole mount E13.5 *Bmp2^lacz/+^* mouse embryo, representative of other *Bmp2^lacz/+^* littermates. (**b,c**) Longitudinal sections through the (**b**) forelimb or (**c**) hindlimb of E14.5 *Bmp2^lacz/+^* mouse embryos. (**d,e**) Longitudinal sections of (**d**) digits or (**e**) radius/ulna of newborn *Bmp2^lacz/+^* mice. (**f--l**) Longitudinal sections through cortical femoral bone from (**f**) 7 day-old, (**g**) 14 day-old, (**h**) 21 day-old or (**i**) 6 month-old *Bmp2^lacz/+^* mice. Abbreviations: PO (periosteum), CB (cortical bone), or MA (marrow) in brackets. (**j--l**) Standardized fractures were established in femurs of *Bmp2^lacz/+^* and WT littermate mice (*n* = 3). (**k,l**) LacZ staining 3 days post-fracture in (**k**) *Bmp2^lacz/+^* or (**l**) negative control WT mice.](elife-42386-fig2){#fig2}

Robust versus quiescent states of periosteal BMP signaling reflect active versus homeostatic states of periosteal bone growth {#s2-4}
-----------------------------------------------------------------------------------------------------------------------------

To compare active BMP signaling with sites of *Bmp2* expression, we utilized transgenic mice expressing enhanced green fluorescent protein (*gfp*) controlled by a pan-BMP-responsive promoter element of the *Id1* gene (*BRE:gfp)* ([@bib33]). At E13.5, GFP+ cells flanked cartilage rudiments of the forelimb ([Figure 3a](#fig3){ref-type="fig"}). In newborn forelimbs, GFP+ cells co-localized with mineralized bone ([Figure 3b](#fig3){ref-type="fig"}), the entire length of the newly-formed bone collar ([Figure 3c](#fig3){ref-type="fig"}, white arrows and red dashed line), as well as hypertrophic cells in growth plate cartilage ([Figure 3c](#fig3){ref-type="fig"}, open red arrows). In hindlimbs at 2 weeks, GFP+ cells surrounded trabecular structures in the medullary cavity and populated the inner layer of the periosteum ([Figure 3d,e](#fig3){ref-type="fig"}, red dashed line). By six months, when mice attained peak skeletal size, GFP expression had become quiescent at bone surfaces and was restricted to pockets of cells in the marrow ([Figure 3f](#fig3){ref-type="fig"}).

![Robust versus quiescent states of periosteal BMP signaling reflect active versus homeostatic states of periosteal bone growth.\
Fluorescent and brightfield microscopy on tissues from mice with transgenic expression of *enhanced green fluorescent protein (gfp)* under the control of a minimal fragment of the *Id1* promoter with pan-BMP response elements (*BRE:gfp*). (**a**) GFP (green) and DAPI (blue) imaging on sagittal (left) or frontal (right) cryosections of the hand plate from E13.5 *BRE:gfp* embryos. (**b,c**) Serial sections through the forelimb of newborn *BRE:gfp* mice were analyzed by Von Kossa staining for mineralized tissue, Alcian Blue staining for cartilage, or DAPI counterstaining of GFP expression domains. (**d,e**) Toluidine blue or GFP/DAPI imaging on sagittal cryosections through the femur of (**d,e**) 2 week-old or (**f**) 6 month-old *BRE:gfp* mice. White arrowheads, GFP in the bone collar surrounding the growth plate cartilage; red arrowheads, GFP+ cells in growth plate; red dotted lines demarcate GFP+ cells of the (**2c**) bone collar or (**2e**) innermost layer of the periosteum. Abbreviations: PO, periosteum; CB, cortical bone; TB, trabecular bone; Ma, Marrow. For all timepoints, *n* ≥ 3 histological sections were examined from equivalent skeletal sites of multiple littermate mice.](elife-42386-fig3){#fig3}

Cells with active BMP pathway are therefore abundant in newly-forming bone at mid-gestation and neonatal stages. A distinct GFP+ population demarcating the bone collar at birth transitions to a robust GFP+ inner periosteal layer flanking the diaphysis by 2 weeks of age, and subsequently remains as a sparsely GFP+ periosteal population in adult bones at homeostasis.

Importantly, *BRE:gfp* is not specific for BMP2 signaling, but rather integrates the net response of a cell to all local BMPs and BMP antagonists. Consistent with the cortical but not trabecular skeletal phenotype of *Bmp2* Prx1-cKO mice ([Figure 1a--u](#fig1){ref-type="fig"}), this comparative analysis of *Bmp2-lacz* versus *BRE:gfp* strongly suggests BMP2 is the major BMP family member driving BMP signaling at periosteal but not necessarily trabecular sites.

*Bmp2* is required for BMP signaling and expression of BMP target genes in the periosteum {#s2-5}
-----------------------------------------------------------------------------------------

We next determined if the periosteum forms in *Bmp2* Prx1-cKO mice and if it engages in BMP signaling. Picrosirius red histology revealed that embryonic development and postnatal maintenance of the periosteum occur independently of *Bmp2* expression in the *Prx1-Cre* lineage ([Figure 4a--c](#fig4){ref-type="fig"}). By contrast, BMP2 is necessary for phospho-activation of Smads1/5 at inner periosteal but not endosteal bone surfaces. This was evident at birth ([Figure 5a](#fig5){ref-type="fig"}) and became pronounced by 2 weeks of age ([Figure 5b](#fig5){ref-type="fig"}). Immunohistochemistry for ID1 protein, a BMP-target gene, showed that ID1+ cells were abundant in the periosteum of WT but not *Bmp2* Prx1-cKO mice ([Figure 5c](#fig5){ref-type="fig"}). We performed in situ hybridization for *Col1a1*, encoding the major extracellular matrix protein produced by osteoblasts. Wild-type but not *Bmp2* Prx1-cKO mice expressed *Col1a1* in the periosteum ([Figure 5d](#fig5){ref-type="fig"}). Periosteal BMP2 signaling is therefore necessary for osteoblast specification in the periosteal niche.

![*Bmp2* is dispensable for development and maintenance of the periosteum.\
(**a,b**) The periosteum forms during development and is maintained in postnatal life in *Bmp2* Prx1-cKO mice. Sagittal sections of the femur from mice were stained with picrosirius red and hematoxylin, and imaged by brightfield (left panels) or polarized light (right panels) microscopy. Images shown are representative of femurs harvested from littermates at ages (**a**) embryonic day 17.5, (**b**) postnatal day 0, or (**c**) postnatal day 14. Arrowheads point to the outer collagen-rich canopy of periosteum in *Bmp2* Prx1-cKO mice.](elife-42386-fig4){#fig4}

![*Bmp2* is essential for periosteal BMP signaling and periosteal expression of BMP target genes.\
(**a,b**) Loss of phospho-Smad1/5+ cells in *Bmp2* Prx1-cKO periosteum. Transverse serial sections of the radius and ulna from (**a**) newborn and (**b**) 2 week-old mice, imaged in brightfield following toluidine blue stain to visualize skeletal tissue (left panels) or by fluorescence microscopy following DAPI and immunostaining to visualize cells with phospho-activated Smads1/5 (right panels). Black boxes on left panels indicate regions expanded in two right panels. (**c**) Loss of ID1+ cells in *Bmp2* Prx1-cKO periosteum. Transverse sections of the radius and ulna were imaged in brightfield following immunostaining to visualize cells expressing the BMP target gene, *Id1*. Black boxes on left panels indicate regions expanded in right panels. (**d**) Toluidine blue and in situ hybridization for *Col1a1* in cross-sections of the radius/ulna from 2 week-old *Bmp2* Prx1-cKO mice. Abbreviations: BC, bone collar/perichondrium; EO, endosteum; PO, periosteum; Ma, marrow. For all timepoints, *n* ≥ 3 histological sections were examined from equivalent skeletal sites of multiple littermate mice.](elife-42386-fig5){#fig5}

*Bmp2* acts downstream of intermittent PTH therapy in the periosteum {#s2-6}
--------------------------------------------------------------------

Intermittent parathyroid hormone (PTH) therapy and sclerostin neutralizing antibody (SOST-ab) are two successful clinical approaches to stimulate the periosteum for periosteal growth and accelerated fracture repair ([@bib1]; [@bib7]; [@bib15]). PTH is a naturally occurring hormone that regulates mineral homeostasis via endocrine actions on multiple organs including bone. Intermittent exposure to PTH (iPTH) through once daily injections of hPTH~1-34~ peptide results in a net surplus of new bone formation ([@bib37]). The mechanism of action for iPTH therapy continues to generate considerable discussion and PTH has been reported to induce expression of *Bmp2* in osteoblast cultures ([@bib54]). To examine the interaction between PTH and *Bmp2* in the periosteum, we treated 2 week-old *Bmp2* Prx1-cKO mice with iPTH for 14 days and monitored periosteal bone growth in the now 1 month-old treated juveniles ([Figure 6a](#fig6){ref-type="fig"}). At 2 weeks of age, WT and *Bmp2* Prx1-cKO mice responded to iPTH with increased trabecular bone mass ([Figure 6b,d,f](#fig6){ref-type="fig"} and [Table 3](#table3){ref-type="table"}). WT but not *Bmp2* Prx1-cKO mice exhibited a trend for periosteal expansion ([Figure 6c,e,g](#fig6){ref-type="fig"} and [Table 3](#table3){ref-type="table"}), although this was not statistically significant and it is plausible that additional treatment time was necessary to achieve sufficient cumulative periosteal growth to become measurable by microCT. WT and *Bmp2* Prx1-cKO mice had elevated serum calcium and reduced serum phosphorus levels following iPTH ([Figure 6l,m](#fig6){ref-type="fig"}). Bone formation rate and mineral apposition rate were significantly blunted at periosteal but not endosteal surfaces of cortical bone in *Bmp2* Prx1-cKO mice, and were not elevated to the levels achieved in WT mice following treatment with iPTH ([Figure 6h--k](#fig6){ref-type="fig"}). WT but not *Bmp2* Prx1-cKO mice treated with iPTH expressed ID3, a BMP target gene, in the periosteum ([Figure 6n](#fig6){ref-type="fig"}), whereas both genotypes had ID3+ cells in endosteal compartments ([Figure 6n](#fig6){ref-type="fig"}, blue lines).

![*Bmp2* acts downstream of intermittent parathyroid hormone treatment in the juvenile periosteum.\
Intermittent PTH~1-34~ therapy does not rescue periosteal growth in juvenile *Bmp2* Prx1-cKO mice. (**a**) Juvenile mice were given intermittent PTH~1-34~ therapy (100 mg/kg, subcutaneous) for 14 days. (**b**) Longitudinal sections of the femur stained with toluidine blue to visualize trabecular bone architecture. (**c**) Transverse sections of the radius and ulna stained with toluidine blue to visualize cortical bone architecture. (**d--g**) Bone mass analyzed in the femur by microcomputed tomography (microCT). (**d**) Trabecular bone at the distal metaphysis and (**e**) cortical bone at the mid-diaphysis of the femur visualized by 3D reconstructions. Images represent the group mean and are shown to scale. (**f**) Ratio of bone volume (BV) to trabecular volume (TV). (**g**) Total cross-sectional area at the mid-diaphysis. Quantitative microCT data presented as mean ±s.d. where \*p\<0.05 vs. matched genotype vehicle control and \#p\<0.05 vs. WT vehicle control (*n* = 4--5 per group). (**h,i**) Dynamic histomorphometry assessing bone formation rate as a function of bone surface (BFR/BS) at (**h**) endosteal versus (**i**) periosteal surfaces. (**j,k**) Dynamic histomorphometry assessing mineral apposition rate (MAR) at (**j**) endosteal versus (**k**) periosteal surfaces. Dynamic histomorphometry (*n* = 4--5 per group) presented as mean ±s.d. where \*p\<0.05. BFR^PO^ *P*-value=0.0503) vs. matched genotype vehicle control and \#p\<0.05 vs. WT vehicle control. (**l,m**) Elisa analysis measuring circulating (**l**) serum phosphate and (**m**) serum calcium in juvenile mice treated with intermittent PTH~1-34~ presented as mean ±s.d. where \*p\<0.05 vs. vehicle-treated *Bmp2^F/F^* or \*\*p\<0.05 vehicle-treated *Bmp2* Prx1-cKO littermates. (**n**) Transverse sections of the radius/ulna with immunostaining to visualize cells expressing the BMP target gene, ID3. Abbreviations: PO, periosteum; Ma, marrow. *n* ≥ 3 histological sections were examined from multiple mice per cohort.](elife-42386-fig6){#fig6}

10.7554/eLife.42386.015

###### Skeletal phenotype of juvenile *Bmp2^Flox/Flox^; Prx1-Cre* mice after intermittent PTH therapy.

Juvenile mice (two weeks-old) were given intermittent PTH~1-34~ therapy (100 mg/kg, subcutaneous) for 14 days. Bone mass was analyzed in the femur by microcomputed tomography (microCT). Trabecular bone at the distal metaphysis and cortical bone at the mid-diaphysis of the femur are presented as group mean ± s.d. and statistically compared by 2-way ANOVA. BV/TV, bone volume fraction; Conn.D, connectivity density; SMI, structure model index; Tb.N, trabecular number; Tb.Th, trabecular thickness; Tb.Sp, Trabecular separation; Tt.Ar, total cross-sectional area; Ct.Ar, cortical bone area; Ct.Ar/Tt.Ar, cortical area fraction; Ct.Th, average cortical thickness; *I*min, minimum moment of inertia; Ma.V, marrow volume. *P*^a^ ≤ 0.05 vs. WT. *P*^b^ ≤0.05 vs. Vehicle.

  MicroCT femur, four wk   *Bmp2^Flox/Flox^*   *Bmp2^Flox/Flox^; Prx1-Cre*                          
  ------------------------ ------------------- ----------------------------- ---------------------- ----------------------
  N                        4                   5                             5                      5
  BV/TV (%)                11.9 ± 7.4          33.2 ± 8.6**^b^**             8.7 ± 1.2              39.2 ± 9.6**^b^**
  Conn.D                   244.6 ± 232.1       438.7 ± 165                   132.2 ± 60.5           702.8 ± 168**^b^**
  SMI                      2.2 ± 0.9           0.1 ± 1.8                     2.7 ± 0.2              −0.6 ± 1.0**^b^**
  Tb.N (1/mm)              5.1 ± 2.1           8.3 ± 2.4**^b^**              4.8 ± 0.5              10.8 ± 1.3**^b^**
  Tb.Th (mm)               0.04 ± 0.005        0.05 ± 0.009                  0.034 ± 0.002**^a^**   0.051 ± 0.006**^b^**
  Tb.Sp (mm)               0.2 ± 0.07          0.121 ± 0.05                  0.2 ± 0.02             0.08 ± 0.02**^b^**
  Ct.Ar (mm^2^)            0.43 ± 0.04         0.60 ± 0.05**^b^**            0.4 ± 0.03             0.5 ± 0.05**^b^**
  Tt.Ar (mm^2^)            1.4 ± 0.1           1.6 ± 0.2                     0.7 ± 0.09**^a^**      0.8 ± 0.1
  Ct.Ar/Tt.Ar (%)          0.31 ± 0.01         0.38 ± 0.02**^b^**            0.57 ± 0.02**^a^**     0.63 ± 0.05
  Ct.Th (mm)               0.1 ± 0.007         0.134 ± 0.004**^b^**          0.15 ± 0.015**^a^**    0.19 ± 0.01**^b^**
  Ma.V (mm^3^)             1.16 ± 0.7          1.2 ± 0.2                     0.42 ± 0.09**^a^**     0.37 ± 0.07
  *I*min (mm^4^)           0.06 ± 0.009        0.1 ± 0.02**^b^**             0.03 ± 0.006**^a^**    0.04 ± 0.01

In adults treated for two weeks with iPTH ([Figure 7a](#fig7){ref-type="fig"}), WT and *Bmp2* Prx1-cKO mice had increased trabecular bone mass following iPTH ([Figure 7b](#fig7){ref-type="fig"} and [Table 4](#table4){ref-type="table"}). To evaluate biomechanical properties in the femur, peak moment (maximum load during failure in three-point bending ([@bib30])) was plotted as a function of I~MIN~/C~MIN~. WT mice experienced much greater cortical expansion with iPTH than *Bmp2* Prx1-cKO mice, as evident by cross-sectional ratio proportional to bending moment ([Figure 7c](#fig7){ref-type="fig"}), and moment of inertia that is predominantly influenced by the periosteal perimeter ([Table 4](#table4){ref-type="table"}). Functionally, iPTH-treated *Bmp2* Prx1-cKO mice were 2--4 times more likely than non-iPTH treated knockouts to experience femoral fracture ([Figure 7e](#fig7){ref-type="fig"}). Forelimb fractures in *Bmp2* Prx1-cKO mice treated with iPTH shifted from unilateral to bilateral occurrence ([Figure 7f,g](#fig7){ref-type="fig"}). Fracture incidence was not improved by increasing iPTH therapy to 3 weeks. Existing fractures remained unhealed ([Figure 7h](#fig7){ref-type="fig"}).

![*Bmp2* acts downstream of intermittent parathyroid hormone treatment in the adult periosteum.\
Intermittent PTH~1-34~ therapy does not improve biomechanical stability or fracture repair in adult *Bmp2* Prx1-cKO mice. (**a**) Adult mice were given intermittent PTH~1-34~ therapy (100 mg/kg, subcutaneous) for (**b--g**) 14 days or (**h**) 21 days. (**b--d**) Quantitative microCT and biomechanical analysis on adult mice treated 2 weeks with PTH~1-34~ (*n* = 3--5), presented as mean ±s.d. where \*p\<0.05 vs. matched genotype vehicle control. (**b**) Ratio of bone volume (BV) to trabecular volume (TV). (**c**) Peak moment as a function of I~MIN~/C~MIN~. (**d**) Predicted minimum moment of inertia. (**e--h**) Incidence of femoral or forelimb fractures in adult mice treated (**e--g**) two weeks (*n* = 4--5 per group) or (**h**) 21 days (*n* = 8 per group) with PTH~1-34~. Biomechanics are reported as mean ±s.d, where *P*-value was calculated using 1-way ANOVA and post-test Newman Keulus. All data points were included in the analysis. Remaining group comparisons were made by 2-way ANOVA and Tukey's multiple comparison tests.](elife-42386-fig7){#fig7}
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###### Skeletal phenotype of adult *Bmp2^Flox/Flox^; Prx1-Cre* mice after intermittent PTH therapy.

Ten week-old mice were given intermittent PTH~1-34~ therapy (100 mg/kg, subcutaneous) for 14 days. Bone mass was analyzed in the femur by microcomputed tomography (microCT). Trabecular bone at the distal metaphysis and cortical bone at the mid-diaphysis of the femur are presented as group mean ±s.d. and statistically compared by 2-way ANOVA. BV/TV, bone volume fraction; Tb.N, trabecular number; Tb.Th, trabecular thickness; Tb.Sp, Trabecular separation; Tt.Ar, total cross-sectional area; Ct.Ar, cortical bone area; Ct.Ar/Tt.Ar, cortical area fraction; Ct.Th, average cortical thickness; Ct.Po, cortical porosity; Ma.V, marrow volume; *I*min, minimum moment of inertia. *P*^a^ ≤ 0.05 vs. WT. *P*^b^ ≤ 0.05 vs. Vehicle.

  MicroCT Femur, 10 wk   *Bmp2^Flox/Flox^*   *Bmp2^Flox/Flox^; Prx1-Cre*                    
  ---------------------- ------------------- ----------------------------- ---------------- -----------------
  N                      5                   5                             5                5
  BV/TV (%)              12.3 ± 3            16.7 ± 2^b^                   15.0 ± 3.0       21.0 ± 1.4^b^
  Tb.N (1/mm)            4.90 ± 0.5          5.50 ± 0.9                    6.10 ± 0.7^a^    5.70 ± 0.6
  Tb.Th (mm)             0.04 ± 0.003        0.04 ± 0.005                  0.04 ± 0.001     0.05 ± 0.003^b^
  Tb.Sp (mm)             0.20 ± 0.02         0.19 ± 0.05                   0.16 ± 0.02      0.16 ± 0.02
  Tt.Ar (mm^2^)          1.60 ± 0.01         1.90 ± 0.3                    0.80 ± 0.08^a^   0.90 ± 0.18
  Ct.Ar (mm^2^)          0.76 ± 0.07         0.88 ± 0.07^b^                0.58 ± 0.06^a^   0.72 ± 0.1b
  Ct.Ar/Tt.Ar (%)        0.47 ± 0.04         0.46 ± 0.03                   0.75 ± 0.01      0.80 ± 0.027
  Ct.Th (mm)             0.19 ± 0.02         0.19 ± 0.005                  0.25 ± 0.01^a^   0.30 ± 0.014^b^
  Ct. Po (%)             3.58 ± 0.28         4.06 ± 0.1^b^                 3.38 ± 0.3       2.80 ± 0.18^b^
  Ma.V (mm^3^)           1.03 ± 0.16         1.21 ± 0.27                   0.23 ± 0.03^a^   0.21 ± 0.07^b^
  *I*min (mm^4^)         0.11 ± 0.01         0.15 ± 0.03^b^                0.03 ± 0.01^a^   0.04 ± 0.02

Expression of *Bmp2* in the *Prx1-Cre* lineage is therefore a major if not essential contributor to the mechanism of action by which iPTH stimulates the periosteum for periosteal bone growth and conclusively essential for the mechanism by which PTH improves bending strength and stimulates the periosteum for fracture repair.

*Bmp2* acts downstream of canonical WNT signaling in the periosteum {#s2-7}
-------------------------------------------------------------------

Haploinsufficiency of *Dkk1*, a secreted antagonist of LRP5/6, enhances canonical WNT signaling and induces high bone mass in mice ([@bib34]), findings that prompted efforts to develop DKK1 neutralizing antibodies for systemic activation of bone formation in clinical orthopedic settings ([@bib22]). Haploinsufficiency of *Dkk1* (*Dkk1^+/-^)* was recently reported to have no effect on the formation or healing of spontaneous fractures in adult mice lacking *Bmp2* (*Dkk1^+/-^; Bmp2^Flox/Flox^; Prx1-Cre*) ([@bib20]). However, DKK1 neutralizing antibodies have been shown to enhance bone formation in younger animals to a greater degree than in older animals ([@bib22]). We therefore revisited this genetic mouse model to determine whether activation of WNT signaling through haploinsufficiency of *Dkk1* could restore periosteal bone growth in young *Bmp2* Prx1-cKO mice, when the skeletal phenotype is first established and thus prior to the onset of fractures ([Figure 8a](#fig8){ref-type="fig"}). By 2 weeks of age, trabecular bone mass was elevated by haploinsufficiency of *Dkk1*, and this was not dependent on *Bmp2* (data not shown). *Bmp2* Prx1-cKO mice developed a ˜75% decrease in calculated cross-sectional moment of inertia at the femoral mid-diaphysis that was neither rescued nor altered by haploinsufficiency of *Dkk1* ([Figure 8b--c](#fig8){ref-type="fig"}).

![*Bmp2* acts downstream of sclerostin neutralizing antibody in the periosteum.\
(**a--c**) Haploinsufficiency of *Dkk1* does not rescue periosteal growth in juvenile *Bmp2* Prx1-cKO mice. Femoral bone mass was analyzed by microCT in juvenile mice (two weeks-old). (**b**) Transverse sections of the femur mid-diaphysis were visualized by 3D reconstructions. Images represent the group mean and are shown to scale. (**c**) Calculated areal moment of inertia. *n* = 6--8 shown as mean ±s.d. \*\*p\<0.005 compared using 2-way ANOVA. (**d--l**) Pharmacologic activation of Wnt pathway does not rescue periosteal growth or fracture repair in adult *Bmp2* Prx1-cKO mice. WT or *Bmp2* Prx1-cKO mice (13 weeks-old) were treated with sclerostin neutralizing antibody (SOST-ab, 20 mg/kg, two times/week for 2 weeks, subcutaneous). Femoral bone mass was analyzed by microCT. (**e**) Trabecular bone at the distal metaphysis and (**g**) cortical bone at the mid-diaphysis of the femur visualized by 3D reconstructions. Images represent the group mean. Scale bars, 1 mm. (**f,h--j**) Quantitative microCT data presented as mean ±s.d. \*p\<0.05, \*\*\*p\<0.005, or \*\*\*\*p\<0.00005. vs. matched genotype vehicle control (*n* = 4--8 per group), compared using 2-way ANOVA and Tukey multiple comparisons test. (**f**) Ratio of bone volume (BV) to trabecular volume (TV) at the distal femoral metaphysis. (**h**) Total cross-sectional area at the mid-diaphysis. (**i**) Polar moment of inertia at the mid-diaphysis. (**j**) Minimum moment of inertia at the mid-diaphysis. (**k,l**) X-ray imaging revealing non-union forelimb fractures in mice treated two weeks with SOST-ab (*n* = 17--24 wrists per group).](elife-42386-fig8){#fig8}

Since haploinsufficiency of *Dkk1* did not affect periosteal growth in young ([Figure 8a--c](#fig8){ref-type="fig"}) or aged mice ([@bib20]), regardless of *Bmp2* status, we chose sclerostin neutralizing antibody (SOST-ab) as an alternative method to stimulate canonical WNT signaling in bone and thereby activate the periosteum. Adult mice were treated for 2 weeks with SOST-ab ([Figure 8d](#fig8){ref-type="fig"}). WT males treated with SOST-ab had a significant increase in trabecular bone (almost 88%). *Bmp2* Prx1-cKO male mice undergoing SOST-ab treatment had ˜32% more trabecular bone than saline treated knockouts, an anabolic trend that reached statistical significance in females but not males ([Figure 8e--f](#fig8){ref-type="fig"}, and Source Data). At the mid-diaphysis ([Figure 8g--j](#fig8){ref-type="fig"}), WT mice treated with SOST-ab significantly enhanced total cross-sectional area (p=0.01; [Figure 8h](#fig8){ref-type="fig"}), minimum moment of inertia (p\<0.0001; [Figure 8i](#fig8){ref-type="fig"}), and polar moment of inertia (p=0.0004; [Figure 8j](#fig8){ref-type="fig"}) when compared to non-treated genotype-matched and sex-matched controls. These parameters of cortical bone mass and strength were unchanged in *Bmp2* Prx1-cKO mice treated with SOST-ab ([Figure 8g--j](#fig8){ref-type="fig"} and Source Data). The number of forelimb fractures in *Bmp2* Prx1-cKO mice was not reduced by SOST-ab ([Figure 8k](#fig8){ref-type="fig"}) and these fractures showed no radiographic evidence of mineralized bridging ([Figure 8l](#fig8){ref-type="fig"}).

The abundance of phospho-activated Smads1/5 in bone lysates ([Figure 9a](#fig9){ref-type="fig"}) and alkaline phosphatase activity in the periosteum ([Figure 9b](#fig9){ref-type="fig"}) were increased 24 hr after one injection of PTH or SOST-ab. Crossing the *BRE:gfp* reporter into a *Bmp2* Prx1-cKO background revealed that SOST-ab dramatically upregulates periosteal BMP signaling in WT but not *Bmp2* Prx1-cKO mice, an effect evident after 72 hr ([Figure 9c](#fig9){ref-type="fig"} and [Figure 9---figure supplement 1](#fig9s1){ref-type="fig"}) or two weeks of treatment ([Figure 9d](#fig9){ref-type="fig"}). The periosteum of *Bmp2^Flox/Flox^; tdTomato ^+/Flox^; Prx1-Cre* mice was populated by tdTomato+ cells despite this lack of periosteal response to SOST-ab ([Figure 9d](#fig9){ref-type="fig"} and [Figure 9---figure supplement 2](#fig9s2){ref-type="fig"}), consistent with our model in which the periosteum is present but not activated ([Figure 3a--f](#fig3){ref-type="fig"}) without complementation by BMP2 ([@bib6]).

![*Bmp2* acts downstream of sclerostin neutralizing antibody to reactivate the developmental periosteal BMP signaling center.\
(**a,b**) PTH~1-34~ and SOST-ab activate BMP signaling in bone and alkaline phosphatase activity in WT mice. Adult WT mice (4 months-old) were given a single injection of PTH~1-34~ (100 mg/kg, subcutaneous) or SOST-ab (20 mg/kg, subcutaneous). (**a**) Immunoblot for total and phospho-activated Smads1/5 in marrow-free bone tissue. Experiment was repeated twice. (**b**) Alkaline phosphatase activity (red) counterstained with DAPI (blue) were imaged on longitudinal sections of the femur (*n* = 2--3 mice per group). (**c--e**) SOST-ab activates BMP signaling in the periosteum in a *Bmp2*-dependent manner. *BRE:gfp* and a Cre-dependent *tdTomato* reporter were bred onto a *Bmp2* Prx1-cKO background. (**c--d**) *BRE:gfp* (green) and (**e**) *tdTomato* (red) was visualized in femurs of adult mice (4 months-old) given 2 injections of (c, top) saline, (c, bottom) 2 injections of SOST-ab (20 mg/kg, subcutaneous) and sacrificed 72 hr after the first injection or (**d--e**) 4 injections of SOST-ab (20 mg/kg, two times/week for 2 weeks, subcutaneous). Abbreviations: Ma, marrow; CB, cortical bone; PO, periosteum.](elife-42386-fig9){#fig9}

Expression of *Bmp2* in the *Prx1-Cre* lineage is therefore essential to the mechanism of action by which SOST-ab stimulates the periosteum for periosteal bone growth and fracture repair.

*Bmp2* functions downstream of canonical WNT signaling in the osteoblast gene regulatory network {#s2-8}
------------------------------------------------------------------------------------------------

Periosteal cells isolated from long bones of 2 week-old mice express *Bmp2* and *Bmp7* mRNAs, but nearly undetectable levels of *Bmp4*. Cre-mediated deletion of *Bmp2* is highly efficient in *Bmp2* Prx1-cKO cells and does not induce *Bmp7* or *Bmp4* to compensate ([Figure 10a,b](#fig10){ref-type="fig"}). Primary periosteal cells from *Bmp2* Prx1-cKO mice were unable to be expanded or maintained without complementation by recombinant BMP2. Cells from the bone marrow stroma (BMSC) or embryonic mouse limb bud were therefore employed for mechanistic studies since we have previously demonstrated that unresponsiveness of *Bmp2*-deficient osteoprogenitors to canonical WNT signaling can be recapitulated using these in vitro models ([@bib47]). In BMSC, an optimal ratio of BMP to WNT signaling must be maintained for osteoblast differentiation ([Figure 10c,d](#fig10){ref-type="fig"}). *Bmp2* Prx1-cKO cells exposed to Wnt3a do not upregulate *Sp7* (a transcription factor required for osteoblast specification ([@bib42]; [@bib36]) unless supplemented with recombinant BMP2 ([@bib47]). Consistent with the observation that *Bmp7* is expressed ([Figure 10b](#fig10){ref-type="fig"}) but does not compensate for lack of *Bmp2* in periosteal cells in vivo, equivalent concentrations of recombinant BMP7 and GDF5 did not functionally compensate in vitro for lack of BMP2 in BMSC ([Figure 10e](#fig10){ref-type="fig"}).

![Deposition of mineralized bone matrix is optimal when BMP2 and canonical Wnt signaling are balanced.\
(**a,b**) Primary periosteal cells isolated from 4 week-old *Bmp2^F/F^* and *Bmp2^F/F^; Prx1-Cre* mice were analyzed by QPCR in three repeat experiments. Fold change mRNA is reported as mean ±s.d. compared by two-tailed student's *t*-test where p\*\<0.001 vs. *Bmp2^F/F^* cells. *Bmp4* expression was at the limit of detection. Primary BMSC were differentiated in osteogenic medium (OM) plus recombinant growth factors. (**c**) Calcified matrix was assessed on day 10 by alizarin red staining (2.5X, brightfield). Cultures were performed in duplicate using pooled cell populations from *n* = 2 *Bmp2^F/F^* or *n* = 4 *Bmp2^F/F^; Prx1-Cre* mice. (**d**) Quantification of alizarin red in (**c**). Error bars represent distribution of two independent experiments. (**e**) Primary BMSC cells from *n* = 3 *Bmp2^F/F^* and *n* = 4 *Bmp2^F/F^; Prx1-Cre* mice were differentiated as non-pooled cultures in OM plus recombinant growth factors as indicated. QPCR analysis on day three was reported as mean ±s.d. compared by two-tailed student's *t*-test where *P*\*\<0.001 vs. *Bmp2^F/F^* cells in OM; *P*^\#^\<0.001 vs. *Bmp2^F/F^; Prx1-Cre* cells in OM; *n* = number of independent cultures per condition.](elife-42386-fig10){#fig10}

*Bmp2* Prx1-cKO cells exposed to Wnt3a also do not upregulate Grainyhead-like 3 (*Grhl3*), a transcription factor co-expressed with *Bmp2* and *Lrp5/6* during embryonic skeletal development and fracture repair in adult bones ([@bib47]). In vitro analysis suggested Grhl3 is necessary and sufficient for induction of *Sp7* by BMP2 ([@bib47]). We thus investigated the relationship between WNT, BMP2, *Sp7*, and *Grhl3* in the osteoblast gene regulatory network and used cells from the mouse embryonic limb bud for the following reasons: early post-natal cortical bone where our phenotype of interest occurs, derives from the embryonic bone collar that forms at the perichondrium at ˜E15.5; this bone collar is made by *Sp7+* cells that first emerge at the perichondrium at E13.5 ([@bib42]), subsequently populate the post-natal periosteum and persist for the first month of life ([@bib29]); *Sp7+* cells that appear at E13.5 are specified from lateral plate mesoderm of the *Prx1+* limb bud ([@bib38]; [@bib31]); *Prx1+* limb bud first appears at ˜E9.5 ([@bib27]). The gene regulatory network that specifies *Sp7+* cells that make the bone collar and populate the early postnatal periosteum must therefore be highly active in the limb bud between E9.5-E13.5.

In a WNT-ON state, activated canonical WNT transcription factor complexes, comprised of β-catenin and co-factors such as Pygo and Bcl9 ([@bib50]), assemble at genomic WNT-responsive elements via interaction with DNA-binding members of the TCF/LEF family. In a WNT-OFF state, TCF/LEF proteins are constitutively bound to chromatin where they function as transcriptional repressors of their bound target genes. Since TCF pulldown is therefore not able to discriminate between genes that are being repressed or induced, we performed anti-Bcl9 ChIP-sequencing ([@bib4]) to define genomic loci targeted by canonical WNT signaling in E10.5 mouse limb buds ([Figure 11a](#fig11){ref-type="fig"}). We discovered 2099 high-confidence Bcl9 peaks enriched at gene loci involved in limb, skeletal, and bone morphogenesis ([Figure 11b](#fig11){ref-type="fig"}) along with previously established canonical WNT target genes to confirm that the strategy had worked ([Figure 11c,d](#fig11){ref-type="fig"}). KEGG pathway analysis also revealed prominent association of Bcl9 peaks with WNT, TGF-beta, Shh, and Hippo pathways ([Figure 11b](#fig11){ref-type="fig"}). Importantly, Bcl9 peaks marked multiple regions, including transcriptional start sites, surrounding *Bmp2* and *Grhl3* loci, suggesting direct transcriptional regulation ([Figure 11e,f](#fig11){ref-type="fig"}). A Bcl9 peak downstream of *Sp7* did not pass statistical threshold. WNT-dependent transcription is therefore already active but does not directly target *Sp7* in the E10.5 limb bud, compatible with the observation that *Sp7+* osteoblasts do not appear until ˜E13.5 ([@bib42]). Consistent with the conclusion that *Bmp2* is a WNT target gene, recombinant Wnt3a induced *Bmp2* in limb bud cells ([Figure 11---figure supplement 1a](#fig11s1){ref-type="fig"}).

![*Bmp2* is a direct target gene of canonical Wnt pathway in osteoblast progenitors.\
(**a**) Cartoon summarizing discovery of canonical WNT target genes by anti-Bcl9 chromatin immunoprecipitation from E10.5 mouse limb buds, deep sequencing, and bioinformatic analysis of peaks. 2099 high-confidence peaks passed statistical threshold in two independent experiments, with significant enrichment at genetic loci associated with (**b**) limb, skeletal, and bone development as well as Wnt, TGF-beta, Shh, and Hippo signaling pathways. High-confidence peaks surrounding genetic loci for (**c**) *Axin2,* (**d**) *Lef1*, (**e**) *Bmp2,* and (**f**) *Grhl3*. Bioinformatic and statistical analysis are described in methods.](elife-42386-fig11){#fig11}

By contrast, chromatin IP qPCR analysis on E13.5 mouse limb bud cells ([Figure 12a](#fig12){ref-type="fig"}) revealed BMP-dependent recruitment of Smad1 and Grhl3 to a genomic site 13 kb upstream of *Sp7* ([Figure 12b,c](#fig12){ref-type="fig"}). This site was enriched for active chromatin histone marks and evolutionarily conserved ([Figure 12c](#fig12){ref-type="fig"}), supporting a cis-regulatory function. In turn, Sp7 is essential for bone formation through direct cis-regulatory control of *Col1A1* ([@bib19]). This major extracellular matrix protein produced by osteoblasts expressed in wild-type but not *Bmp2* Prx1-cKO periosteum ([Figure 5d](#fig5){ref-type="fig"}).

![*Bmp2* acts downstream of canonical Wnt pathway to specify *Sp7+/Col1A1*+ osteoblasts.\
(**a**) Cartoon summarizing regulatory analysis of *Sp7* locus by chromatin immunoprecipitation of H3-acetyl-K14, Smad1, endogenous Grhl3, or transiently expressed V5-GRHL3 from chromatin of immortalized E13.5 limb bud cell cultures grown in presence of recombinant BMP2 or Noggin. (**b**) QPCR analysis revealed BMP-dependent enrichment of these proteins at a putative consensus-binding motif for Grhl3 located at a (**c**) highly conserved genomic region ˜13 kb upstream of the *Sp7* transcription start site. Data reflect mean ±distribution in two independent experiments.](elife-42386-fig12){#fig12}

Human variants of *BMP2* and *GRHL3* are associated with increased risk of fracture {#s2-9}
-----------------------------------------------------------------------------------

*BMP2* variants predicted to result in haploinsufficiency are associated with short stature, craniofacial gestalt, skeletal anomalies, and congenital heart disease ([@bib51]). To further evaluate the clinical consequences of *BMP2* variation, we performed a phenomewide association study of *BMP2* and a downstream effector *GRHL3* in 61,062 individuals from DiscovEHR (<http://www.discovehrshare.com/>), a cohort linking exome sequence data to electronic health records (EHRs) ([@bib12]). Using a Bonferroni significance threshold of p\<1.86e-7 for 268,192 association results, we observed three significant associations for *BMP2* and six significant associations for *GRHL3*. Of note, there was a significant association between a missense variant in *BMP2* (p.Arg131Ser) and increased risk of lower leg fracture (odds ratio (OR) 16.05, 95% confidence interval (CI) 6.44--40.00, p=2.54e-9), consistent with previous data on *BMP2* haploinsufficiency and observations in the conditional knockout mouse. Moreover, significant associations were observed between a synonymous variant in *GRHL3* and increased risk of fracture of thoracic vertebra (OR = 12.72, 95% CI 5.59--28.94, p=1.36e-9) and between an intronic variant in *GRHL3* and increased risk of fracture of patella (OR = 13.33, 95% CI 5.11--34.81, p=1.22e-7) ([Table 5](#table5){ref-type="table"}).

10.7554/eLife.42386.026

###### Human variants of *BMP2* and *GRHL3* are associated with increased risk of fractures.

We performed a phenomewide association study of *BMP2* and a downstream effector *GRHL3* in 61,062 individuals from DiscovEHR, a cohort linking exome sequence data to electronic health records (EHRs). Using a Bonferroni significance threshold of p\<1.86e-7 for 268,192 association results, we observed three significant associations for *BMP2* and six significant associations for *GRHL3*.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variant          Gene          Functional Prediction   HGVS amino acid                                   Phenotype                                                 Odds Ratio\     *P-* Value   MAF
                                                                                                                                                                     (CI)                         
  ---------------- ------------- ----------------------- ------------------------------------------------- --------------------------------------------------------- --------------- ------------ ---------
  20:6770235:T:G   *BMP2*        missense                p.Ser37Ala                                        Post-eruptive color changes of dental hard tissues        15.44\          5.33E-10     0.01802
                                                                                                                                                                     (6.50--36.64)                

  20:6778359:G:A   *BMP2*        missense                p.Arg154Gln                                       Secondary hyperparathyroidism, not elsewhere classified   18.88\          1.06E-09     0.00033
                                                                                                                                                                     (7.35--48.53)                

  1:24336821:A:T   ***GRHL3***   synonymous              p.Pro202Pro:p.Pro156Pro:p.Pro207Pro:p.Pro202Pro   **Fracture of thoracic vertebra**                         12.72\          1.36E-09     0.00078
                                                                                                                                                                     (5.59--28.94)                

  20:6778291:A:T   ***BMP2***    missense                p.Arg131Ser                                       **Fracture of lower leg, including ankle**                16.05\          2.54E-09     0.00019
                                                                                                                                                                     (6.44--40.00)                

  1:24342967:C:T   *GRHL3*       missense                p.Thr454Met:p.Thr408Met:p.Thr459Met:p.Thr454Met   Atresia of bile ducts                                     17.11\          2.07E-08     0.03395
                                                                                                                                                                     (6.34--46.18)                

  1:24336694:T:C   *GRHL3*       missense                p.Val160Ala:p.Val114Ala:p.Val165Ala:p.Val160Ala   Malignant neoplasm of parietal lobe                       8.72\           2.31E-08     0.04732
                                                                                                                                                                     (4.08--18.64)                

  1:24344928:A:G   *GRHL3*       missense                p.Asn484Ser:p.Asn438Ser:p.Asn489Ser:p.Asn484Ser   Malignant neoplasm of parietal lobe                       8.23\           3.24E-08     0.0484
                                                                                                                                                                     (3.90--17.38)                

  1:24339645:C:G   ***GRHL3***   intronic                NA                                                **Fracture of patella**                                   13.33\          1.22E-07     0.00109
                                                                                                                                                                     (5.11--34.81)                

  1:24342967:C:T   *GRHL3*       missense                p.Thr454Met:p.Thr408Met:p.Thr459Met:p.Thr454Met   Atresia of esophagus with tracheo-esophageal fistula      9.76\           1.63E-07     0.03396
                                                                                                                                                                     (4.16--22.88)                
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

In summary, our data demonstrate that skeletal development, fracture repair, and therapeutic response to systemic treatment with PTH or SOST-ab all converge on expression of *Bmp2* in the periosteal niche for control of osteoblast specification and periosteal function ([Figure 13a](#fig13){ref-type="fig"}).

![Developmental, reparative, and therapeutic signals converge on *Bmp2* to specify osteoblasts in the periosteal niche.\
(**a**) A proposed hierarchical and regionalized gene regulatory network, summarizing the source and identity of signals that regulate transcription of *Bmp2* for downstream specification of *Sp7+/Col1A1*+ osteoblasts in the periosteal niche. Boxed regions, biological compartments; Boxed text, inputs evaluated in this study; Double arrows in a link, communication across territories; Flat footpads ending at genetic loci, transcriptional inhibition; Pointed footpads ending at genetic loci, transcriptional induction; Diamonds under footpads, evidence of direct cis-regulatory interaction provided by our study; White bubbles, protein/protein interactions. Made with [Biotapestry.org](http://www.biotapestry.org/).](elife-42386-fig13){#fig13}

Discussion {#s3}
==========

Whereas the signaling mechanisms controlling longitudinal growth by the growth plate were initially described in 1996 ([@bib25]; [@bib53]), the mechanisms underlying periosteal growth by the periosteum, the primary determinant of bone width and therefore bone strength, have remained unknown. Here we reveal that *Bmp2* governs all thus-far identified developmental, clinically-inducible and repair functions of the periosteum. *Bmp2* is dispensable for periosteum formation, but essential for osteoblast differentiation from periosteal progenitors, and thereby periosteal bone growth and fracture repair. Local BMP2 expression regulates BMP signaling in the periosteal niche during this process and drives periosteal response to canonical WNT and PTH signals.

Global loss of *Bmp2* is embryonic lethal, explaining why the identity of a signal controlling periosteal bone growth, a postnatal function, eluded us for so long. The slender bone phenotype in *Bmp2* Prx1-cKO mice, established by 2 weeks of age, is not recapitulated by omission of any other BMP from bone ([@bib46]), nor is it present when *Bmp2* is deleted in more specified skeletal progenitors expressing *Sp7-EGFP::Cre* or *2.3kb-Col1a1-Cre*.

Our work reveals the innermost layer of periosteum as a robust BMP signaling center and identifies pre-*Sp7* +progenitors as a critical source and target for BMP2. Cells in the outer periosteum and within cortical bone are not highly engaged in BMP signaling. BMP2 availability in bone therefore appears to be tightly regulated, perhaps through sequestration of BMP2 in the extra-cellular matrix. Comparative analysis of *Bmp2^lacz^* with *BRE:gfp* strongly suggests that cortical bone matrix functions as a BMP2 repository, allowing only local activation of cells at the innermost cambial periosteal layer. Future studies uncovering the mechanisms that restrict BMP2 bioavailability to the periosteum could uncover new strategies to improve bone width, resistance to fracture, and bone repair.

Excessive LRP5/6 signaling underlies several human skeletal disorders characterized in part by exuberant periosteal expansion ([@bib1]). Strikingly however, periosteal growth and fracture repair defects in *Bmp2 cKO* mice were not rescued by haploinsufficiency of *Dkk1*, iPTH therapy, or treatment with SOST-ab. We propose that LRP5/6-dependent pathways initiating periosteal bone formation in the postnatal skeleton converge on upregulation of *Bmp2* for induction of BMP signaling. BMP2 signaling, by coordinating assembly of a Smad/Grhl3 complex at the *Sp7* genomic locus, thereby acts downstream of canonical WNT to specify the *Sp7+/Col1A1*+ cells required for periosteal growth and fracture repair.

Looking forward, we find a lack of information and understanding of the signals mediating normal BMP2 expression in the periosteal niche, both as a function of age and in the context of skeletal disease. This information is key to modulating skeletal stem cell behavior to improve healing and in response to therapeutic agents. As all of our experiments are done in the total absence of periosteal BMP2, the information needed to figure out this part of the puzzle remains elusive, especially since deposition of BMP2 in bone and new synthesis of BMP2 are both missing in our mice. An abundance of cis-regulatory elements in the BMP2 gene desert mediate precise spatiotemporal control of BMP2 during development and repair, and this could potentially be exploited for screens identifying improved and more controlled methods of bone repair mediated by endogenous expression of *Bmp2*.

In summary, the dynamic spatiotemporal expression pattern of *Bmp2* constitutes an essential mechanism determining active versus quiescent states of the periosteal niche throughout embryonic and postnatal life. We identify *Bmp2* as the signal that couples bone length to bone width during development and demonstrate that reactivation of this developmental signaling center is the essential mechanism by which bone anabolic therapies recruit the periosteum to reduce fracture risk and accelerate fracture repair.

Materials and methods {#s4}
=====================

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\      Designation                     Source or reference   Identifiers                                                                            Additional\
  (species)\                                                                                                                                                      information
  or resource                                                                                                                                                     
  ------------------ ------------------------------- --------------------- -------------------------------------------------------------------------------------- -----------------------
  Gene\              bone morphogenetic\                                   MGI:MGI:88177                                                                          
  (*Mus musculus*)   protein 2 (*Bmp2*)                                                                                                                           

  Genetic\           Tg(Prrx1-cre)1Cjt;\             PMID:17194222         MGI:3700047;\                                                                          
  reagent\           Bmp2tm1Cjt/Bmp\                                       RRID:[MGI:3700047](https://scicrunch.org/resolver/MGI:3700047)                         
  (*Mus musculus*)   2tm1Cjt                                                                                                                                      

  Genetic\           B6.Cg-Tg\                       PMID:16854976         IMSR JAX:006361;\                                                                      
  reagent\           (Sp7-tTA,tetO-EGFP/cre)1Amc/J                         RRID:[IMSR_JAX:006361](https://scicrunch.org/resolver/IMSR_JAX:006361)                 
  (*Mus musculus*)                                                                                                                                                

  Genetic\           B6.FVB-Tg(Col1a1-cre)\          PMID:12112477         IMSR:RBRC05603; RRID:[IMSR_RBRC05603](https://scicrunch.org/resolver/IMSR_RBRC05603)   
  reagent\           1Kry/Rbrc                                                                                                                                    
  (*Mus musculus*)                                                                                                                                                

  Genetic\           Bmp2tm1(KOMP)\                  PMID:29198724         MGI:5912401;\                                                                          
  reagent\           Vlcg/Bmp2+                                            RRID:[MGI:5912401](https://scicrunch.org/resolver/MGI:5912401)                         
  (*Mus musculus*)                                                                                                                                                

  Genetic\           BRE:gfp                         PMID:18615729                                                                                                
  reagent\                                                                                                                                                        
  (*Mus musculus*)                                                                                                                                                

  Genetic\           Dkk1tm1Lmgd/\                   PMID:17127040;\       MGI:3618757;\                                                                          
  reagent\           Dkk1tm1Lmgd                     PMID:11702953         RRID:[MGI:3618757](https://scicrunch.org/resolver/MGI:3618757)                         
  (*Mus musculus*)                                                                                                                                                

  Genetic\           B6.Cg-Gt(ROSA)26\               Jackson Laboratory    IMSR JAX:007909;\                                                                      
  reagent\           Sortm9(CAG-tdTomato)\                                 RRID:[IMSR_JAX:007909](https://scicrunch.org/resolver/IMSR_JAX:007909)                 
  (*Mus musculus*)   Hze/J                                                                                                                                        

  Cell line\         MLB13 Clone 14                  PMID:7532346;\                                                                                               
  (*Mus musculus*)                                   PMID:8302904                                                                                                 

  Transfected\       V5-tagged GRHL3                 Center for Cancer\    PlasmID_clone:\                                                                        
  construct\                                         Systems Biology       HsCD00376192                                                                           
  (*H. sapien*)                                                                                                                                                   

  Antibody           anti-Id1\                       Santa Cruz            Santa Cruz\                                                                            Immunostaining\
                     (rabbit polyclonal)                                   Biotechnology:sc-488;\                                                                 (1:100)
                                                                           RRID:[AB_631701](https://scicrunch.org/resolver/AB_631701)                             

  Antibody           anti-Id3\                       Santa Cruz            Santa Cruz\                                                                            Immunostaining\
                     (mouse polyclonal)                                    Biotechnology:sc-490;\                                                                 (1:100)
                                                                           RRID:[AB_2123010](https://scicrunch.org/resolver/AB_2123010)                           

  Antibody           anti-pSmad1/5/8\                Cell Signaling\       Cell Signaling\                                                                        Western (1:1000);\
                     (rabbit monoclonal)             Technologies          Technology:9511;\                                                                      Immunostaining (1:50)
                                                                           RRID:[AB_331671](https://scicrunch.org/resolver/AB_331671)                             

  Antibody           anti-Smad1\                     Cell Signaling\       Cell Signaling\                                                                        Western (1:1000);\
                     (rabbit polyclonal)             Technologies          Technology:9743;\                                                                      ChIP (1:25)
                                                                           RRID:[AB_2107780](https://scicrunch.org/resolver/AB_2107780)                           

  Antibody           anti-alpha-Tubulin\             Sigma-Aldrich         Sigma-Aldrich:T6074;\                                                                  Western (1:1000)
                     (mouse monoclonal)                                    RRID:[AB_477582](https://scicrunch.org/resolver/AB_477582)                             

  Antibody           anti-V5-tag\                    Abcam                 Abcam Cat:ab27671;\                                                                    ChIP (1:250)
                     (mouse monoclonal)                                    RRID:[AB_471093](https://scicrunch.org/resolver/AB_471093)                             

  Antibody           anti-GRHL3\                     Thermo Fisher         Thermo Fisher\                                                                         ChIP (1:100)
                     (rabbit polyclonal)                                   Scientific:PA5-41616;\                                                                 
                                                                           RRID:[AB_2606412](https://scicrunch.org/resolver/AB_2606412)                           

  Antibody           anti-H3acK14\                   Millipore             Millipore:06--599;\                                                                    ChIP (1:100)
                     (rabbit polyclonal)                                   RRID:[AB_2115283](https://scicrunch.org/resolver/AB_2115283)                           

  Antibody           anti-Bcl9\                      Abcam                 Abcam:ab37305;\                                                                        ChIP (1 μg)
                     (rabbit polyclonal)                                   RRID:[AB_2227890](https://scicrunch.org/resolver/AB_2227890)                           

  Software,\         Biotapestry                     Biotapestry.org;\                                                                                            
  algorithm                                          PMID:15907831;\                                                                                              
                                                     PMID:18757046;\                                                                                              
                                                     PMID:27134726                                                                                                
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Animals {#s4-1}
-------

In vivo experiments were performed in compliance with the Guide for the Care and Use of Laboratory Animals and were approved by the Harvard Medical Area Institutional Animal Care and Use Committee (protocol \#04043 to V.R.). Mice bearing alleles where loxP sites flank the coding sequence of exon 3 of *Bmp2* (*Bmp2^F/F^*) were bred to *Prx1-Cre* mice (*B6.Cg-Tg(Prrx1-cre*)1Cjt/J) ([@bib27]), *Sp7-GFP::Cre* mice (B6.Cg-Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/J) ([@bib42]), or 2.3kb-*Col1A1-Cre* mice (*Tg(Col1a1-cre)1Kry*) ([@bib8]) to obtain *Bmp2^Flox/Flox^; Prx1-Cre* mice (*Bmp2* Prx1-cKO), *Bmp2^Flox/Flox^; Sp7-EGFP::Cre* mice (*Bmp2* Sp7-cKO), or *Bmp2^Flox/Flox^; Col1a1-Cre* mice (*Bmp2* Col1a1-cKO). Mice carrying floxed *Bmp2* alleles (*Bmp2^Flox/Flox^*) were crossed to *Dkk1* haploinsufficient mice (*Dkk1tm1Lmgd/Dkk1tm1Lmgd*) ([@bib35]) to obtain *Dkk1^+/-^; Bmp2^Flox/Flox^ mice*, and these mice were subsequently bred to *Bmp2^+/Flox^; Prx1-Cre* mice to obtain *Dkk1^+/-^; Bmp2^Flox/Flox^; Prx1-Cre* mice (*Dkk1^+/-^; Bmp2* Prx1-cKO). *Bmp2* Prx1-cKO mice were also crossed to Ai9 Cre-reporter mice (*B6.Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J*) harboring a loxP-flanked STOP cassette preventing transcription of a CAG promoter-driven red fluorescent protein variant (*tdTomato*). The targeted mutation was inserted into the *Gt(ROSA)26Sor* locus by homologous recombination. TdTomato is expressed when bred to mice that express Cre recombinase.

Mice with a *lacZ* cassette knock-in to the endogenous *Bmp2* locus (*Bmp2^tm1(KOMP)Vlcg/+^*), herein referred to as *Bmp2^lacz^*) were generated by the trans-NIH Knock Out Mouse Project (KOMP) and obtained from the KOMP repository ([www.komp.org](http://www.komp.org)). The genomic region of the *Bmp2* containing exon two was deleted and replaced with a transmembrane-lacZ/neo cassette using bacterial homologous recombination. Transgenic mice expressing enhanced green fluorescent protein under the control of a BMP-responsive fragment of the *Id1* promoter (herein referred to as *BRE:gfp*) ([@bib33]) were a kind gift of Dr. Christine Mummery.

Bone measurements {#s4-2}
-----------------

Femoral length and width (antero/posterior) were measured in fresh collected bones using a digital caliper (Ted Pella, Inc) (8--20 per age and per genotype). Percentage of tissue area and cross-sectional composition ([Figure 1](#fig1){ref-type="fig"}) were calculated based on areal measurements obtained with ImageJ Software areal measurement tool. The whole radius from newborn (*n* = 6--9) and P14 (*n* = 3--9) *Bmp2 Prx1-*cKO mice and control littermates were sectioned from distal to proximal. One section every 50 µm was measured. Digital images were obtained using a Zeiss AxioImager MI Microscope fitted with an AxioCam HRC digital camera and Zeiss AxioVision imaging software.

Radiographs {#s4-3}
-----------

Imaging was done post-mortem in a Bruker MS-Fx-Pro using 45 kVp of radiation energy and a 30 s exposure time.

**Micro-CT and bone strength assessment**  {#s4-4}
------------------------------------------

Femora were scanned post-mortem with a μCT40 (Scanco Medical AG, Switzerland). The mid-shaft of the diaphysis was analyzed using a 12 µm voxel size, 70 kVp/145 mA of radiation energy and a 300 msec integration time. Contouring was performed using a threshold of 220 for trabecular bone (450.7 mgHA/cm^3^) or 334 for cortical bone (787.7 mgHA/cm^3^). We quantified the average moment of inertia (I~MIN~), and the average total cross-sectional area of bone tissue (Ct.Ar). To assess structural strength, hydrated femurs were loaded in three-point bending to determine the peak moment (maximum force x span) endured by each bone ([@bib30]). For the estimated material properties reported in supplemental materials, we used standard flexural formula (maximum force x span x C~MIN~/I~MIN~) from beam theory the structural properties from microCT. Data are reported as mean ±s.d, where p-value was calculated using 1-way ANOVA and post-test Newman Keulus. All data points were included in the analysis.

Intermittent parathyroid hormone {#s4-5}
--------------------------------

Two week-old *Bmp2* Prx1*-*cKO mice and control littermates were assigned to treatment groups (*n* = 5--8 per group). PTH~1-34~ (hPTH(1--34); Bachem, Bubendorf, Switzerland) was administered at 100 µg/kg/day ([@bib24]) for 2 weeks by subcutaneous injections or equivalent volume of vehicle (phosphate-buffered saline, pH 7.4) seven days per week. Seven week-old male *Bmp2* Prx1*-*cKO mice and control littermates were treated for 3 weeks with PTH~1-34~ or vehicle five days per week (*n* = 4--8). Mice were sacrificed 2 hr after the final PTH injection, followed by exsanguination and tissue collection for further analysis.

Histomorphometry {#s4-6}
----------------

Static and dynamic histomorphometry measurements were analyzed between 4 week-old or 10 week-old *Bmp2* Prx1*-*cKO mice and control littermates treated or not treated with hPTH. In the first set of experiments (2 to 4 weeks of age) mice were injected with demeclocycline hydrochloride (40 mg/kg) for 4 days before euthanasia and with calcein (20 mg/kg) 1 day before euthanasia ([@bib16]). In the second set of experiments (7 to 10 weeks of age) the same doses of demeclocycline and calcein were administered, but 8 and 2 days before euthanasia ([@bib18]). Kinetic bone parameters were obtained from unstained 10 μm sections examined by fluorescent light microscopy. The static and dynamic histomorphometric indexes were evaluated in trabecular and cortical bone in sagittal and transversal sections. Periosteal and endosteal parameters were evaluated as described previously ([@bib32]).

Sclerostin-neutralizing antibody  {#s4-7}
---------------------------------

SOST-ab (provided by A. Economides at Regeneron) was prepared in sterile saline and delivered via subcutaneous injection at a dose of 20 mg/kg, twice per week for 2 weeks. Diluted antibody was stored in single-use aliquots at −80°C.

Histology {#s4-8}
---------

Samples removed for histology were fixed in 4% paraformaldehyde, decalcified in Tris buffer containing 10% EDTA and embedded in paraffin. Sections (5 mm thick) were stained with 0.1% toluidine blue using standard procedures. Immunolocalization was performed as described ([@bib41]; [@bib28]). Briefly, sections were digested with trypsin (1% in PBS) for 10 min at 37°C and then boiled for 15 min in citrate buffer ([@bib21]). Sections were blocked with 5% goat serum for 1 hr and incubated with primary antibody overnight at 4°C, followed by incubation with secondary antibody for 1 hr at room temperature, then with fluorophore for 30 min at room temperature or incubated with Vector Elite ABC reagent (Vector) for 60 min before developing with diaminobenzidine. Primary antibodies were as follows: anti-pSMADS (Cell Signaling); anti-ID1 and ID3 (BioCheck); anti-IGF1 (Abcam). Secondary antibodies were conjugated with AlexaFluor-555 and AlexaFluor-488 for immunofluorescence and sections were counterstained with DAPI (Vectashield). Secondary antibodies were conjugated with biotin for immunohistochemistry and sections were counterstained with toluidine blue or methyl green. Digital images were obtained using a Zeiss AxioImager MI Microscope fitted with an AxioCam HRC digital camera and Zeiss AxioVision imaging software.

Standardized fractures {#s4-9}
----------------------

with pin stabilization were made in femora of adult mice as previously described ([@bib52]). Fractured and non-fractured contralateral controls femurs were collected 3 days after fracture, processed for paraffin sectioning, and subjected to lacZ staining.

LacZ staining {#s4-10}
-------------

Tissues were embedded in optimal cutting temperature compound (OCT) on dry ice and frozen sections were prepared for beta-galactosidase staining as previously described ([@bib23]).

Cryohistology for endogenously expressed reporters {#s4-11}
--------------------------------------------------

Tissues were fixed in 10% neutral buffered formalin overnight at room temperature. If necessary, tissues were decalcified in 14% EDTA pH 8.0 prior cryopreservation in a 30% sucrose gradient, then embedded in optimal cutting temperature compound (OCT) on dry ice. Frozen sections from adult bones were collected on a CryoJane tape system and mounted with Vectashield plus DAPI (Vector Labs).

*Col1A1* in situ hybridization {#s4-12}
------------------------------

P14 mouse hindlimbs were fixed, paraffin processed and sectioned in the coronal plane using standard methods. In vitro transcription to generate riboprobes was performed using standard protocols and reagents (Promega). In situ hybridization with digoxigenin-labeled *Col1A1* probe was carried out as described previously ([@bib17]).

Three-point bending {#s4-13}
-------------------

Femurs were placed on the lower support points of a three-point bending fixture with the anterior side down (*i.e.*, bending about the medial-lateral plane). The span (*L*) between the lower supports was 7 mm or 8 mm depending on genotype. Hydrated bone was loaded-to-failure at 3.0 mm/min (Dynamight 8841, Instron, Canton, OH) to generate the force vs. displacement (P-d) curve. The primary structural properties were rigidity (δ), which is the slope of the linear portion of the curve multiplied by *L* ([@bib39])/48, ultimate moment (P~u~ ×*L*/4), which is the peak bending moment endured by the mid-shaft, the post-yield deflection (PYD), which is the normalized displacement at failure minus the displacement at yielding, and work-to-fracture (W~f~), which is the area under the normalized P-d curve generated by the test (i.e., multiplied by 12/*L2* to adjust for differences in span).

Serology {#s4-14}
--------

Blood was collected by heart puncture after euthanasia for serum biochemistry. Serum IGF-1 was measured with ELISA kit (Immuno diagnostics, Inc, CA, USA) from 2-, 4- and 10-week-old mice. Analysis was performed as suggested by the manufacturer and, in all cases, serum was diluted 1:10.

Recombinant growth factors {#s4-15}
--------------------------

Recombinant human BMP2 (200 ng/ml; Genetics Institute). Recombinant human BMP7 and GDF5 (200 ng/ml; R and D Systems). Recombinant mouse Wnt3a, Wnt10 (40 ng/ml; R and D Systems). Noggin (10 ug/ml; R and D Systems).

Immunoblot {#s4-16}
----------

Bones were cleaned of soft tissue and marrow, snap frozen in liquid nitrogen, and pulverized for 10 min using a Bullet Blender and Navy Lysis Beads in RIPA buffer containing Halt protease and phosphatase inhibitors (Pierce). Proteins were separated by SDS-page electrophoresis and immunoblotted with the following antibodies at 1:1000 dilutions: phospho-Smad1/5 (Cell Signaling \#9511), Smad1 (Cell Signaling \# 9743), and alpha-Tubulin (Sigma, \#T6074).

Bone marrow stromal cells (BMSC) {#s4-17}
--------------------------------

Bone marrow from 4 to 6 month-old mice (male and female) was collected as previously described ([@bib45]) and plated in BMSC medium (ascorbic acid free α-MEM (Invitrogen) containing 20% FBS, 40 mM L-glutamine, 100 U/ml penicillin-G, and 100 mg/ml streptomycin). After 3 days, non-adherent cells were removed by vigorous washing. Osteoblast differentiation BMSC were seeded in BMSC medium at 35,000 cells/well in 96-well dishes (for alizarin red staining) or 300,000 cells per well in 24-well dishes (for RNA or protein). Confluent cultures were stimulated on day one with Osteogenic Medium (OM: BMSC medium plus 50 μg/ml ascorbic acid and 10 mM β-glycerophosphate)±200 ng/ml rhBMP2 (Genetics Institute) or 40 ng/ml recombinant mouse Wnt3a (R and D Systems). **Alizarin red** Fixed cells were stained for 30 mins in 0.4% aqueous solution of alizarin red S (Sigma). ARS was eluted in 10% glacial acetic acid, pH was adjusted with 10% ammonium hydroxide, and absorbance was measured at 405 nm. **QPCR** Cells were scraped into 250 μl/well of Trizol, homogenized five times through a 22 g needle and five times through a 25 g needle. Genomic DNA was digested with 50 ul gDNase solution (RNeasy Plus Universal Kit, Qiagen). The organic phase was separated using 50 μl chloroform, and mixed with 150 μl of 70% ethanol before loading onto an RNeasy spin column and purifying according to manufacturer's instructions. RNA was reverse transcribed with EcoDry Premix (Clonetech). Data were normalized to *beta-actin*, analyzed using ΔΔCT method, and expressed as mean ±s.d relative to *Bmp2^F/F^* cells cultured in osteogenic medium. Two-tailed student's *t*-test was utilized to calculate *P*-values.

Periosteal cells {#s4-18}
----------------

Periosteal cells were isolated from hindlimbs and forelimbs of 4 week-old *BMP2^F/F^; Prx1-Cre* mice. Litter mate *BMP2^F/F^* or *BMP2^F/+^: Prx1-Cre* were used as controls. In brief, long bone were carefully cleaned from muscles and the ends of the bones sealed with agarose. The bones were digested with collagenase and dispase 3 mg/ml (Sigma) for 45 min in a shaking 37°C water bath. Cells were collected, strained and plated in 5% CO2% and 5% O2 incubator. After expansion RNA was extracted. Cells from *BMP2^F/F^; Prx1-Cre* mice do not grow well, so cultures were supplemented with 10 ng/ml rBMP2. For each isolation bones from 3 to 4 mice/genotype were pooled to create one culture. Three separate isolations were performed for gene expression analysis. 500 ng RNA was reverse transcribed to cDNA using the iSCRIPT kit (BioRad) and qPCR analysis performed (SYBR GREEN). The data presented as mean ± SEM. BMP4 was detected only in one of the samples.

Chromatin immunoprecipitation {#s4-19}
-----------------------------

Immortalized and clonal limb bud cells from E13.5 mouse embryos (MLB13 clone 14) ([@bib43]; [@bib44]) were cultured and maintained in DMEM supplemented with 10% fetal bovine serum and Pen/Strep. MLB13 clone 14 cells were generated by Vicki Rosen and maintained continuously in Dr. Rosen\'s private storage. They remain neomycin-resistant (based on the strategy for immortalization) and maintain historical features of morphology and differentiation capacity in skeletal lineages. They are free of mycoplasma, as determined by QPCR testing. A plasmid encoding V5-tagged GRHL3 was provided by Center for Cancer Systems Biology, PlasmID clone HsCD00376192. MLB13 were seeded to 90% confluence, transfected with a plasmid encoding human GRHL3, and cultured for 3 d in osteogenic medium plus indicated growth factors. Chromatin immunoprecipitation was performed according to manufacturer's instructions with the SimpleChIP Enzymatic Chromatin IP Kit with magnetic beads (Cell Signaling). Primers for Grhl3 binding element 11 are: Forward 5'-ACCTGGGTATTGCCTGAAAA-3' and Reverse 5'-GGAAGAGCTGGCTTCTTTGA-3'. V5-antibody: Invitrogen \#R961-25. GRHL3 antibody: ThermoFisher \#PA5-41616. H3acK14 antibody: Millipore \#06--599. Rabbit IgG: Cell Signaling \#2729. Smad1 antibody: Cell Signaling \#9743.

Chromatin immunoprecipitation/sequencing {#s4-20}
----------------------------------------

Forelimbs buds were manually dissected from ca. 250 RjOrl:SWISS outbred 10.5 dpc mouse embryos. Chromatin immunoprecipitation was performed as previously described ([@bib3]). Briefly, the tissue was dissociated to a single cell suspension with collagenase (1 ug/ml in PBS) for 1 hr at 37° C, washed and crosslinked in 20 ml PBS for 40 min with the addition of 1.5 mM ethylene glycol-bis(succinimidyl succinate) (Thermo Scientific, Waltham, MA, USA), for protein-protein crosslinking ([@bib49]), and 1% formaldehyde for the last 20 min of incubation, to preserve DNA-protein interactions. The reaction was blocked with glycine and the cells were subsequently lysed in 1 ml HEPES buffer (0.3% SDS, 1% Triton-X 100, 0.15 M NaCl, 1 mM EDTA, 0.5 mM EGTA, 20 mM HEPES). Chromatin was sheared using Covaris S2 (Covaris, Woburn, MA, USA) for 8 min with the following set up: duty cycle: max, intensity: max, cycles/burst: max, mode: Power Tracking. The sonicated chromatin was diluted to 0.15% SDS and incubated overnight at 4°C with 1 μg of anti-Bcl9 (Abcam, ab37305) or IgG and 50 ul of protein A/G magnetic beads (Upstate). The beads were washed at 4°C with wash buffer 1 (0.1% SDS, 0.1% deoxycholate, 1% Triton X-100, 0.15 M NaCl, 1 mM EDTA, 0.5 mM EGTA, 20 mM HEPES), wash buffer 2 (0.1% SDS, 0.1% sodium deoxycholate, 1% Triton X-100, 0.5 M NaCl, 1 mM EDTA, 0.5 mM EGTA, 20 mM HEPES), wash buffer 3 (0.25 M LiCl, 0.5% sodium deoxycholate, 0.5% NP-40, 1 mM EDTA, 0.5 mM EGTA, 20 mM HEPES), and finally twice with Tris EDTA buffer. The chromatin was eluted with 1% SDS, 0.1 M NaHCO3, de-crosslinked by incubation at 65°C for 5 hr with 200 mM NaCl, extracted with phenol-chloroform, and ethanol precipitated. The immunoprecipitated DNA was used as input material for DNA deep sequencing. ChIP-seq data are available at Array Express accession number E-MTAB-7652.

Peak calling {#s4-21}
------------

All sequenced reads were mapped using the tool for fast and sensitive reads alignment, Bowtie 2 (<http://bowtie-bio.sourceforge.net/bowtie2/index.shtml>), onto the UCSC mm10 reference mouse genome. The command 'findPeaks' from the HOMER tool package (<http://homer.salk.edu/homer/>) was used to identify enriched regions in the Bcl9 immunoprecipitation samples using the '-style = factor' option (routinely used for transcription factors with the aim of identifying the precise location of DNA-protein contact). Input and IgG samples were used as enrichment-normalization controls. Peak calling parameters were adjusted as following: L = 4 (filtering based on local signal), F = 4 (fold-change in target experiment over input control). Annotation of peaks\' position (i.e. the association of individual peaks to nearby annotated genes) was obtained by the all-in-one program called 'annotatePeaks.pl'. Finally, the HOMER command 'makeUCSCfile' was used to produce bedGraph formatted files that can be uploaded as custom tracks and visualized in the UCSC genome browser (<http://genome.ucsc.edu/>).

Association analyses in the DiscovEHR cohort {#s4-22}
--------------------------------------------

Sample preparation and sequencing was performed as described previously. Exome capture was performed with either NimbleGen (SeqCap VCRome). Sequence reads were aligned to GRCh38. Variant calling and genotyping was performed as described in detail previously ([@bib12]). Gene definitions were restricted those genes and transcripts with annotated start and stop codons; a total of 19,467 protein-coding genes.

Genotypes were coded as follows: homozygous reference as 0, heterozygotes as 1, and homozygous alternative or compound heterozygous as 2. Only individuals of European ancestry were analyzed. For clinical diagnoses, ICD-10 codes were collapsed into hierarchical clinical disease groups and corresponding controls using a modified version of the groupings proposed previously ([@bib10]; [@bib11]). Case assignment for the 14,128 ICD-10 based diagnoses required one or more of the following: a problem list entry of the diagnosis code or an encounter diagnosis code entered for two separate clinical encounters on different calendar days. Firth logistic regression was performed using PLINKv1.9 ([@bib5]), with adjustment for age, age squared, sex, and the first four principal components of ancestry. Gene-trait association results meeting the Bonferroni corrected significance threshold 0.05/268192 (p\<1.86--7) are reported.

Statistical analysis {#s4-23}
--------------------

Methods for statistical analysis are specific to various components of the study and are described in detail for each type of experiment.
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The DiscoverEHR human dataset is published and publicly available at <http://www.discovehrshare.com>. Using search terms \'BMP2\' and \'GRHL3\' and a Bonferroni significance threshold of P \< 1.86e-7 for 268,192 association results, we observed three significant associations for BMP2 and six significant associations for GRHL3. Mouse limb bud ChIP-sequencing data are available through ArrayExpress website <https://www.ebi.ac.uk/arrayexpress> and accession \#E-MTAB-7652.

The following dataset was generated:
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Reactivation of a Developmental *Bmp2* Signaling Center is Required for Therapeutic Control of the Periosteal Niche\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Harry Dietz as the Senior Editor. The following individual involved in review of your submission has agreed to reveal her identity: Karen Lyons (Reviewer \#1). The other reviewers remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Overall there was significant enthusiasm for the work, which was felt to be novel and potentially important for the field, particularly in regards to the role of BMP2 downstream of Wnts in the periosteum. There were concerns which should be addressed however in the revision. There is a need to clarify the ChipSeq data; There was a question about role of other BMPs besides BMP2 in the periosteum, and more discussion about the notable finding that neither PTH nor anti SOST antibodies reversed the fracture phenotype of the cKOs; furthermore there remain some questions about the skeletal phenotype of the cKOs especially in the limb that will require an additional figure.

*Reviewer \#1:*

This is a thorough characterization of the unique periosteal phenotype in *Bmp2* mutant mice. Using a combination of in vivo and ex vivo approaches, the authors show that the *Bmp2* mutant phenotype results from loss of local production of *Bmp2* expression in PRx1+ve progenitors. The histomorphometry showing increased osteocyte numbers in cortical bone suggests that in the absence of BMP2, progenitors differentiate prematurely. The data also show that the differentiation itself is impaired. These are important discoveries. So is the discovery of a BMP signaling center in the inner periosteum. This finding alone will attract high interest among bone biologists. Furthermore, the authors show that exogenous GDF5 and BMP7 cannot compensate for BMP2. This is a surprising and very important finding, hinting that relative affinities of ligands for their receptors is decisive for cell fate decisions by progenitors. A large amount of data is presented in this manuscript, encompassing phenotypic, transcriptome and ChIP-seq analysis, and human exome sequence data to document that BMP2 acts downstream of Wnts to activate expression of Sp7. The discussion is concise and the authors do an outstanding job distilling a great deal of experimental evidence to support their important conclusions.

*Reviewer \#2:*

In this study, the authors have further examined the roles on BMP2 in postnatal periosteal bone growth and functioning. The data indicate that ablation of *Bmp2* in the Prx1-Cre lineage is sufficient to impair not only long bone width growth, but also fracture repair and response to anabolic bone therapies such as intermittent PTH or sclerostin antibody treatment. Additional data indicate that BMP2 acts downstream of LRP5/6 signaling since periosteal and fracture defects in *Bmp2*;Prx1-Cre mutants were not rescued by haplo-insufficiency of Dkk1 or treatment with SOST antibody. ChIP and deep sequencing data suggest that BMP2 affects expression of Sp7 (required for osteoblast differentiation) by recruitment of Smad1 and Grhl3 at conserved regulatory elements. Re-examination of DiscovEHR data sets pointed to links between BMP2 and GRHL3 variants and increased fracture risks in patients. The authors conclude that *Bmp2* expression in periosteal progenitors accounts for all the key postnatal functions of this tissue, including long bone width, fracture repair and anabolic responses.

This is an important and comprehensive study from a group who has contributed much and in an original manner to this area of biomedical research. For the most part, the data are strong and convincing and do strengthen the argument that BMP2 plays a rather unique and non-redundant role in establishing the phenotypic properties and repair capacity of periosteum. As the authors stress, future identification of means to stimulate periosteal BMP2 action or expression could lead to new therapies to strengthen or repair bone. There are only a few and relatively minor concerns.

A key conclusion reached is that \"although many BMPs are expressed in bone, periosteal BMP signaling and bone formation require only *Bmp2* in the Prx1-Cre lineage\". It would be important to know whether *Bmp2* ablation may have resulted in changes in expression of other Bmps, particularly in periosteum. Also, given that Prx1-Cre does not target only the periosteal progenitors but the entire mesenchymal cell population within the limbs, it would be important for the authors to discuss possible changes in tissue interactions within the mutant limbs influencing outcomes.

As the authors correctly underline, it is quite interesting that Dkk1 haploinsufficiency and treatment with iPTH or SOST antibody did not appear to rescue periosteal growth and fracture repair defects in the *Bmp2*;Prx1-Cre mice. In fact, the latter treatments increased the frequency of spontaneous fractures in mutant mice. The authors mention, but do not deal with, this striking outcome, and it would be important to not only face it, but also try to account for it.

The ChIP-sequencing data in Figure 6 are somewhat perplexing as they were generated using whole E10.5 mouse limb buds and immortalized E13.5 limb bud cells in vitro. Both of these represent early embryonic and highly heterogenous cell populations, and it is hard to know to what extent they speak (or can speak) about the function of selected genes (Axin2, Lef1 and Grhl3) specifically in periosteal cells. The fact that *Bmp2* ablation does not affect embryonic long bone development and that bone formation has not started by E13.5 also question the significance of the data.

*Reviewer \#3:*

This manuscript from Salazar and colleagues presents information of potential interest to many in the field. While the concepts being addressed are of interest, there are numerous points that should be clarified that are listed below.

1\) Please show the bone phenotypes (Figure 1) for Prx1-*Bmp2* heterozygotes if they are available. Please show a schematic diagram or a reference on *Bmp2*-Lacz allele (Figure 2A).

2\) Although LacZ staining and GFP fluorescence (Figure 2) show *Bmp2* expression and *Bmp2* activation nicely, sometimes the signal could be too weak to detect due to the limitation of the techniques. Such as there is a significant *Bmp2* activation (GFP, Figure 1U) in the adult bone marrow, but there is no *Bmp2* expression (LacZ, Figure 1H and I) at the same place. So, a qPCR with different bone fractions by serial collagenase digestion of cortical bone would be a good confirmation on the location of Bmp2 in different stages.

3\) No Col1a1 expression in WT/cKO osteocytes within the cortical bone (Figure 3F)?

4\) *Bmp2*-Prx1 cKO appears to not affect iPTH-induced trabecular bone gain (Figure G and N). The author claims that *Bmp2* is a mediator of iPTH for periosteal bone formation. However, there was no significant change in periosteal expansion in either WT or cKO mice (Figure 4H). It is also not clear why there was a significant increase in periosteal bone formation in the cKO mice as well (Figure 4J and L).

5\) Figure 4M is a little confusing. According to Figure 2H, *Bmp2* is expressed in adult bone osteocytes (not periosteal cells). However, iPTH only induces ID3 in only periosteal cells but not osteocytes themselves. Is this suggesting that osteocytes do not respond to *Bmp2* although they express *Bmp2*? The reviewer is also confused by the cKO bone morphology in Figure 4M, which shows massive woven bones and relative stronger (compared with the WT) ID3 expression in osteocytes.

6\) Figure 4Q-T do not have error bars or statistical analysis done.

7\) What does no Imin change in *Bmp2* cKO mice mean in Figure 5I?

8\) It is convincing that *Bmp2* cKO inhibits anti-SOST-induced bone expansion (Figure 5G-J). Since there is no bone phenotype when *Bmp2* is deleted in osteoblasts (Sp7-cre or Col1-cre) and BV/TV is normal in Prx1-*Bmp2* cKO mice (Figure 4G and N), it appears that Bmp2 is important for periosteum, but not for trabecular bone formation. What is the hypothesis that BV/TV cKO is not increased by anti-SOST (Figure 5F) other than development versus treatment?

9\) Please provide an additional and higher powered picture for Figure 5O. It seems that all Prx1+ cells are BRE/GFP+ while all Prx1- cells are BRE/GFP-.

10\) Also, please provide an additional picture without DAPI/blue fluorescence for Figure 5N to show GFP in the periosteum.

11\) Compare the result of Bcl9 ChIP-seq in limbs with publicly available Tcf4/β-catenin Chipseq data in other tissues/cell lines in terms of pathway enrichments. Is there a reason to choose Bcl9 antibody over Tcf4 antibody?

12\) Bmp2 is proposed to be a direct downstream target of canonical Wnt signaling (Figure 6E) in limb buds. Does Wnt3a treatment directly induce Bmp2 mRNA in limb bud cells?

13\) Are the authors proposing that Bmp2-Sp7-Col1a1 cascade is only present in the periosteum, but not in cortical bone or trabecular bone?

10.7554/eLife.42386.033

Author response

Reviewer \#2:

> \[...\] This is an important and comprehensive study from a group who has contributed much and in an original manner to this area of biomedical research. For the most part, the data are strong and convincing and do strengthen the argument that BMP2 plays a rather unique and non-redundant role in establishing the phenotypic properties and repair capacity of periosteum. As the authors stress, future identification of means to stimulate periosteal BMP2 action or expression could lead to new therapies to strengthen or repair bone. There are only a few and relatively minor concerns.
>
> A key conclusion reached is that \"although many BMPs are expressed in bone, periosteal BMP signaling and bone formation require only Bmp2 in the Prx1-Cre lineage\". It would be important to know whether Bmp2 ablation may have resulted in changes in expression of other Bmps, particularly in periosteum.

New data in Figures 10A-B show that *Bmp7* is also expressed in the periosteum and therefore does not compensate for loss of *Bmp2*. This is fully consistent with the in vitro data showing that recombinant BMP7 does not compensate for loss of *Bmp2* in primary osteoblast cultures. Expression of *Bmp4* in periosteal cells was at the lower limit of detection by QPCR and therefore also cannot compensate for lack of *Bmp2*.

> Also, given that Prx1-Cre does not target only the periosteal progenitors but the entire mesenchymal cell population within the limbs, it would be important for the authors to discuss possible changes in tissue interactions within the mutant limbs influencing outcomes.

Based on our *Bmp2-lacZ data*, we do not see evidence of *Bmp2* expression that would influence other tissue interactions within the mutant limbs and that it is likely that if BMP signaling is required for those interactions, other BMPs present in the limb would provide the signal. While it is somewhat surprising that BMP2 would have such a highly specific role in limb skeletogenesis, the role is fully consistent with the *Bmp2-lacZ* localization pattern. As genetic ablation of *Bmp4* or *Bmp7* do not affect periosteal apposition but have other ligand-specific effects on the limb skeleton (2008 Tsuji, 2010 Tsuji, and 2006 Bandyopadhyay), we believe ligand localization is a major determinant of this phenotype.

> As the authors correctly underline, it is quite interesting that Dkk1 haploinsufficiency and treatment with iPTH or SOST antibody did not appear to rescue periosteal growth and fracture repair defects in the Bmp2;Prx1-Cre mice. In fact, the latter treatments increased the frequency of spontaneous fractures in mutant mice. The authors mention, but do not deal with, this striking outcome, and it would be important to not only face it, but also try to account for it.

We observed increased frequency of spontaneous fractures only with iPTH treatment, as shown in Figures 2-T. It is well established that iPTH activates bone resorption alongside bone formation, where the net effect in wildtype mice is increased bone mass. In the absence of BMP2, activation of bone formation response is severely blunted and thus the altered balance shifts towards increased bone fragility.

> The ChIP-sequencing data in Figure 6 are somewhat perplexing as they were generated using whole E10.5 mouse limb buds and immortalized E13.5 limb bud cells in vitro. Both of these represent early embryonic and highly heterogenous cell populations, and it is hard to know to what extent they speak (or can speak) about the function of selected genes (Axin2, Lef1 and Grhl3) specifically in periosteal cells. The fact that Bmp2 ablation does not affect embryonic long bone development and that bone formation has not started by E13.5 also question the significance of the data.

Question 1) Heterogeneity

\- For E10.5, the ChIP-seq analysis automatically enriches spefically for cells that are actively engaged in canonical Wnt signaling.

\- For E13.5, the immortalized limb bud cells we used are a clonal line of osteochondral-progenitors, not a heterogeneous population (Rosen, 1994).

Question 2) Time points were selected for analysis

\- E13.5 is when Osx1+ osteoblasts and the bone collar (primitive periosteum) first appear (Rodda and McMahon, 2006). These cells persist for the first 30 days of life and directly mediate periosteal bone growth during early post-natal life (Maes, 2010).

Question 3) Function of selected genes

\- *Axin2* and *Lef1* are only used as positive controls to demonstrate that the Bcl9-pulldown method enriches for previously established canonical Wnt target genes.

\- We propose that Grhl3 acts as a co-factor with Smads for induction of *Sp7*. For this to be true, *Grhl3* would need to be induced prior to induction of *Sp7*, and this hypothesis is confirmed in this figure.

Reviewer \#3:

> This manuscript from Salazar and colleagues presents information of potential interest to many in the field. While the concepts being addressed are of interest, there are numerous points that should be clarified that are listed below.
>
> 1\) Please show the bone phenotypes (Figure 1) for Prx1-Bmp2 heterozygotes if they are available. Please show a schematic diagram or a reference on Bmp2-Lacz allele (Figure 2A).

The phenotype of *Bmp2; Prx1-Cre* heterozygotes has been previously shown in Tsuji et al., 2006.

A schematic showing the structure of the *Bmp2-lacZ* allele has been provided in new Figure 2---figure supplement 1A-C.

> 2\) Although LacZ staining and GFP fluorescence (Figure 2) show Bmp2 expression and Bmp2 activation nicely, sometimes the signal could be too weak to detect due to the limitation of the techniques. Such as there is a significant Bmp2 activation (GFP, Figure 1U) in the adult bone marrow, but there is no Bmp2 expression (LacZ, Figure 1H and I) at the same place. So, a qPCR with different bone fractions by serial collagenase digestion of cortical bone would be a good confirmation on the location of Bmp2 in different stages.

We thank the reviewer for the comments and apologize for not being clear about how the signaling reporter works. The *BRE-gfp* reporter is not specific for BMP2 signaling but rather provides a net readout of all BMP signaling. The observation that GFP expression is maintained in the marrow compartment of *Bmp2* cKOs is consistent with the fact that many BMPs besides *Bmp2* have been shown previously by several groups to be expressed in the bone marrow where they contribute to hematopoiesis as well as skeletal biology. By the same rationale, the observation that GFP persists in the marrow of *Bmp2* cKOs while being attenuated in the periosteum, strongly supports our model that other BMPs do not compensate for BMP2 in the periosteum. We propose that BMP2 is the main BMP family member with activity in the periosteum, whereas other BMPs, such as *Bmp4* and *Bmp7* compensate in other compartments (2008 Tsuji, 2010 Tsuji, and 2006 Bandyopadhyay).

> 3\) No Col1a1 expression in WT/cKO osteocytes within the cortical bone (Figure 3F)?

In a lineage-tracing experiment with *Col1a1-Cre*, osteocytes would be indeed be "marked" as descendants of a population that at some point expressed bona fide *Col1a1* mRNA. However, the primary function of bone-embedded osteocytes is no longer matrix-production but mechanical sensing. As part of this change in cell function, osteocytes would not necessarily be expected to be actively transcribing and depositing new *Col1a1* in the surrounding bone as unabated production of collagen would eventually eliminate the lacunar space they occupy. The observation that osteocytes are not transcribing *Col1a1* mRNA, regardless of *Bmp2* expression, is therefore the expected outcome.

> 4\) Bmp2-Prx1 cKO appears to not affect iPTH-induced trabecular bone gain (Figure G and N). The author claims that Bmp2 is a mediator of iPTH for periosteal bone formation. However, there was no significant change in periosteal expansion in either WT or cKO mice (Figure 4H). It is also not clear why there was a significant increase in periosteal bone formation in the cKO mice as well (Figure 4J and L).

Periosteal BFR and MAR are direct readouts of periosteal function while uCT total area is indirect. Increased total area requires a longer amount of time to be measurable compared to increased BFR/MAR since it is a cumulative effect over time of bone forming activity.

> 5\) Figure 4M is a little confusing. According to Figure 2H, Bmp2 is expressed in adult bone osteocytes (not periosteal cells). However, iPTH only induces ID3 in only periosteal cells but not osteocytes themselves. Is this suggesting that osteocytes do not respond to Bmp2 although they express Bmp2? The reviewer is also confused by the cKO bone morphology in Figure 4M, which shows massive woven bones and relative stronger (compared with the WT) ID3 expression in osteocytes.

Figure 2H shows *Bmp2-lacZ* expression in osteocytes of untreated juvenile mice of 2 weeks of age. These data cannot be directly compared to histology in 4M which shows the cortical bone of a 1 month old animal that was treated for the past 2 weeks with iPTH.

The authors thank the reviewer for pointing out the highly porous nature of the PTH-treated cKO cortical bone in Figure 4M. We have used the lamellar structures as guides to distinguish true cortical bone with osteocytes from the intra-cortical pockets of heterogeneous endosteum and marrow. This greatly clarifies that Id3+ nuclei can be found in the periosteum and marrow of PTH-treated WT mice, but not the periosteum of PTH-treated cKO mice. Importantly, osteocytes in cortical bone of PTH-treated mice are Id3-, regardless of *Bmp2* genotype. The data across the paper are therefore consistent in that osteocytes are negative for Id1, Id3, and *Col1a1*, as would be expected for cells that should not be actively engaged in BMP signaling and are not making bone matrix.

> 6\) Figure 4Q-T do not have error bars or statistical analysis done.

Data in Figure 4Q represent an absolute number (% of total animals scored with a binary outcome). Error bars and statistical analysis are therefore not applicable here.

> 7\) What does no Imin change in Bmp2 cKO mice mean in Figure 5I?

Imin is the minimum value of moment of inertia for the bone, which occurs relative to the cross-sectional orientation with the least resistance to bending. Wildtype mice treated with sclerostin antibody exhibit increased Imin while cKO mice exhibit no change. This estimated material property is based on diaphyseal (cortical) morphology obtained by microCT, and predicts that wildtype bones, but not cKO bones are more resistant to bending (and fracture) after treatment.

> 8\) It is convincing that Bmp2 cKO inhibits anti-SOST-induced bone expansion (Figure 5G-J). Since there is no bone phenotype when Bmp2 is deleted in osteoblasts (Sp7-cre or Col1-cre) and BV/TV is normal in Prx1-Bmp2 cKO mice (Fig4G and N), it appears that Bmp2 is important for periosteum, but not for trabecular bone formation. What is the hypothesis that BV/TV cKO is not increased by anti-SOST (Figure 5F) other than development versus treatment?

In Figure 10C, in vitro experiments reveal that BMSC cells exhibit a "bell-shaped curve" response to ectopically activated WNT signaling, where low concentrations of recombinant Wnt3a activate matrix calcification but higher amounts become inhibitory. This inhibitory WNT threshold is lowered in the absence of *Bmp2*, as BMSC lacking *Bmp2* are able to mineralize under normal conditions but not when exposed to recombinant Wnt3a. In other words, the inhibitory WNT threshold is reduced when the net amount of BMP signaling is reduced. in vivo, we hypothesize that endosteal osteoblasts are able to function in an unchallenged environment due to compensation by other BMPs (probably BMP4/7), but that the reduced net strength of pan-BMP signaling has made them more sensitive to Wnt-inhibition. In a future study, this interesting possibility could be measured by monitoring bone mass in *Bmp2; Prx1-Cre* mice treated with decreasing doses of SOST-ab.

> 9\) Please provide an additional and higher powered picture for Figure 5O. It seems that all Prx1+ cells are BRE/GFP+ while all Prx1- cells are BRE/GFP-.

A new supplementary figure with separate images for GFP, DAPI, and RFP channels very clearly shows that the vast majority of cells derived from the *Prx1-Cre; TdTomato* lineage are not actively engaged in BMP signaling (GFP+).

> 10\) Also, please provide an additional picture without DAPI/blue fluorescence for Figure 5N to show GFP in the periosteum.

A new figure panel has been added to Figure 5P.

> 11\) Compare the result of Bcl9 ChIP-seq in limbs with publicly available Tcf4/β-catenin Chipseq data in other tissues/cell lines in terms of pathway enrichments. Is there a reason to choose Bcl9 antibody over Tcf4 antibody?

TCF/LEF proteins are constitutively bound to chromatin. In a WNT-OFF state, they function as transcriptional repressors of their bound target genes. In a WNT-ON state, additional co-factors (such as β-catenin, pygopus, and Bcl9) are recruited to genome-bound TCF, thereby converting TCFs from transcriptional repressors to transcriptional activators. TCF pulldown is therefore not able to discriminate between genes that are being repressed or induced, and thus a co-activator must be used to understand the subset of target genes that are being activated at any given time.

We used Bcl9 pulldown to selectively enrich for loci occupied by transcriptionally active β-catenin (by definition, only in WNT-ON cells). In support of our scientific rationale, Bcl9 mutant mice exhibit defects in distal limb and long bone development, demonstrating at the genetic level that β-catenin transcription in the developing limb is fully dependent on the Bcl9-β-catenin interaction (2018 Cantu Gen Dev).

> 12\) Bmp2 is proposed to be a direct downstream target of canonical Wnt signaling (Figure 6E) in limb buds. Does Wnt3a treatment directly induce Bmp2 mRNA in limb bud cells?

Yes, a new Figure 11---figure supplement 1A shows that *Bmp2* mRNA is upregulated by recombinant Wnt3a.

> 13\) Are the authors proposing that Bmp2-Sp7-Col1a1 cascade is only present in the periosteum, but not in cortical bone or trabecular bone?

We propose that a general BMP-dependent cascade acts upstream of the *Sp7/Col1a1*. In the periosteum, our data provide evidence that this BMP-dependent cascade is activated primarily if not entirely by BMP2. Our study does not address which BMPs compensate for loss of BMP2 at non-periosteal sites. However, it reasonable to hypothesize that the major compensatory BMP at non-periosteal sites is BMP4, since mice with compound loss of *Bmp2* and *Bmp4* in *Prx1-Cre* lineage fail to make an appendicular skeleton (2006 Bandyopadhyay) while mice with loss of only *Bmp2* manifest a periosteal-specific phenotype.

[^1]: These authors contributed equally to this work.
